Prediction in Therapeutic Effectiveness Research: Prolonged Dose Titration in Warfarin Patients and Model Transportability by Finkelman, Brian Steven
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2014
Prediction in Therapeutic Effectiveness Research:
Prolonged Dose Titration in Warfarin Patients and
Model Transportability
Brian Steven Finkelman
University of Pennsylvania, bfin@mail.med.upenn.edu
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Epidemiology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1275
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Finkelman, Brian Steven, "Prediction in Therapeutic Effectiveness Research: Prolonged Dose Titration in Warfarin Patients and Model
Transportability" (2014). Publicly Accessible Penn Dissertations. 1275.
http://repository.upenn.edu/edissertations/1275
Prediction in Therapeutic Effectiveness Research: Prolonged Dose
Titration in Warfarin Patients and Model Transportability
Abstract
Therapeutic effectiveness research relies heavily on prediction modeling, as improving therapeutic outcomes
for individuals often requires being able to predict which patients are likely to do poorly on a given therapy. In
this dissertation, we examine the specific case of patients starting warfarin therapy, many of whom are at
higher risk of bleeding and thrombotic events because they take a long time to determine their optimal
therapeutic dose. Additionally, we examine the general problem of transportability of clinical prediction
models and whether that problem can be improved through sequential model updating. Specifically, we
conducted three projects with the following goals: 1) To determine the social, clinical, and genetic factors
associated with time to maintenance dose in patients starting warfarin; 2) To develop and externally validate a
prediction model of prolonged dose-titration in these patients; and 3) To determine whether sequential
model updating can improve model transportability in a simulation study. Being able to predict which patients
are likely to experience prolonged dose titration on warfarin could help clinicians and patients decide whether
to use warfarin or a less burdensome alternative oral anticoagulant. Furthermore, the overall utility of this and
other clinical prediction models could be greatly increased by strategies that improve model transportability,
such as sequential model updating.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Epidemiology & Biostatistics
First Advisor
Stephen Kimmel
Keywords
anticoagulation, clinical prediction, therapeutic effectiveness, updating, warfarin
Subject Categories
Epidemiology
This dissertation is available at ScholarlyCommons: http://repository.upenn.edu/edissertations/1275
PREDICTION IN THERAPEUTIC EFFECTIVENESS RESEARCH: PROLONGED DOSE 
TITRATION IN WARFARIN PATIENTS AND MODEL TRANSPORTABILITY  
 
Brian Steven Finkelman 
A DISSERTATION 
in 
Epidemiology and Biostatistics 
Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2014 
Supervisor of Dissertation    
__________________________               
Stephen Kimmel, MD, MSCE   
Professor of Medicine and Epidemiology 
 
Graduate Group Chairperson 
__________________________ 
John Holmes, PhD, Professor of Medical Informatics in Epidemiology 
Dissertation Committee 
Benjamin French, PhD  
Assistant Professor of Biostatistics 
 
Scott Kasner, MD 
Professor of Neurology and Emergency Medicine 
 
Stephen Kimmel, MD, MSCE 
Professor of Medicine and Epidemiology 
 
Michael Levy, PhD 
Assistant Professor of Epidemiology 
 
David Margolis, MD, PhD 
Professor of Dermatology and Epidemiology 
 
 
 
 
 
 
 
 
 
PREDICTION IN THERAPEUTIC EFFECTIVENESS RESEARCH: PROLONGED DOSE 
TITRATION IN WARFARIN PATIENTS AND MODEL TRANSPORTABILITY  
 
 
 
 
 
 
 
 
 
 
 
COPYRIGHT 
 
2014 
Brian Steven Finkelman 
 
iii 
 
 
 
 
 
 
 
 
 
 
 
 
To my father, 
who saved a place on his shelf 
for this dissertation 
for 28 years. 
 
 
 
 
  
iv 
 
ACKNOWLEDGMENT 
 
First, I would like to thank my funding sources over the last four and a half years: 
5F30HL115992, which was awarded to me by NHLBI; 5R01HL066176, which was awarded to 
my mentor, Stephen Kimmel, by NHLBI; the NIH MSTP grant for the University of 
Pennsylvania Perelman School of Medicine, T32-GM07170; and institutional funds from the 
Center for Therapeutic Effectiveness Research, the Center for Pharmacoepidemiology Research 
and Training, and the University of Pennsylvania. Completing a dissertation is much easier with a 
roof overhead and a full stomach. 
 
A huge acknowledgement must be made to my mentor Stephen Kimmel. We began working 
together the summer following my first year of medical school, and he has always been a 
wonderful and supportive advisor. His commitment to make time for his students, despite an 
extremely busy schedule, is really exceptional, and it has made all the difference for me. I would 
also like to thank my biostatistics advisor, Benjamin French, who encouraged me to always seek 
the best method, and then made sure that I actually understood it. The rest of my committee—
David Margolis, Scott Kasner, and Michael Levy—provided me with invaluable comments on 
my dissertation, helping me to improve the quality and rigor of the work. A special thank you, 
also, to Michael Levy, Benjamin French, Ari Friedman, and Elena Prager, who introduced me to 
data analysis in R, a statistical program that made many parts of this dissertation possible. Thank 
you also, Elena, for your help with editing this massive document. 
 
Additionally, I would like to acknowledge the staff who helped to ensure that I had the data for a 
dissertation in the first place: Luanne Bershaw, who probably sees Case Report Forms in her 
sleep by now; Colleen Brensinger, who turned those forms into a database that was actually 
v 
 
usable; and Sandra Barile, who made sure that all of us showed up to our meetings at the right 
place and time. I would also like to thank Jennifer Kuklinski and Gabrielle Ostapovich at the 
Office of Graduate Training in the Center for Clinical Epidemiology and Biostatistics for their 
help with navigating the maze of graduate degree requirements. Additionally, I would like to 
thank John Holmes, the director of the PhD program, who has worked tirelessly for many years to 
help make the PhD program in Epidemiology what it is today. Finally, I want to thank all of the 
individuals at the MD/PhD program office—and, particularly, Maggie Krall, Maureen Kirsch, 
and Skip Brass—for providing an impossible amount of logistical and mental support. Without 
their efforts, I would have probably continued toiling away at my PhD for another year or two 
before figuring out a way to finish. 
 
Last but not least, I would like to extend thanks to all of the friends and family who supported me 
over these many years. To my father, Richard, who always made sure that I was working to finish 
the next paper or grant, and to my mother, Ellen, who always made sure that I did not kill myself 
in the process. To my sister, Andrea, who always encouraged me to work on research that was 
meaningful in the real world. And, finally, to my wonderful wife and partner, Elena, for helping 
me through all the daily struggles that go along with finishing a PhD and for making me look 
forward to coming home at the end of every long day of work. 
  
vi 
 
ABSTRACT 
 
PREDICTION IN THERAPEUTIC EFFECTIVENESS RESEARCH: PROLONGED DOSE 
TITRATION IN WARFARIN PATIENTS AND MODEL TRANSPORTABILITY 
Brian Steven Finkelman 
Stephen Kimmel 
 
Therapeutic effectiveness research relies heavily on prediction modeling, as improving 
therapeutic outcomes for individuals often requires being able to predict which patients are likely 
to do poorly on a given therapy. In this dissertation, we examine the specific case of patients 
starting warfarin therapy, many of whom are at higher risk of bleeding and thrombotic events 
because they take a long time to determine their optimal therapeutic dose. Additionally, we 
examine the general problem of transportability of clinical prediction models and whether that 
problem can be improved through sequential model updating. Specifically, we conducted three 
projects with the following goals: 1) To determine the social, clinical, and genetic factors 
associated with time to maintenance dose in patients starting warfarin; 2) To develop and 
externally validate a prediction model of prolonged dose-titration in these patients; and 3) To 
determine whether sequential model updating can improve model transportability in a simulation 
study. Being able to predict which patients are likely to experience prolonged dose titration on 
warfarin could help clinicians and patients decide whether to use warfarin or a less burdensome 
alternative oral anticoagulant. Furthermore, the overall utility of this and other clinical prediction 
models could be greatly increased by strategies that improve model transportability, such as 
sequential model updating. 
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CHAPTER 1. INTRODUCTION 
  
What is therapeutic effectiveness research? The goal of therapeutic effectiveness research is to 
improve public health by increasing the effectiveness of existing therapies as used in clinical 
practice. The effectiveness of a therapy is different from its efficacy, which refers to the average 
effect of a therapy under ideal usage. Efficacy is generally assessed, along with safety, by 
randomized controlled trials to determine whether therapies should be allowed to be brought to 
market. Research on therapeutic effectiveness, thus, seeks to identify the factors that lead to the 
observed discrepancy between a therapy’s efficacy and its effectiveness in real-world usage. 
Therapeutic effectiveness will often depend on a much wider range of factors than efficacy, 
including clinical factors, such as age, comorbidities, and drug-drug interactions; genetic factors, 
such as variants in genes related to a drug’s pharmacodynamic or pharmacokinetic pathways; and 
social/behavioral factors, such as access to health care, health literacy, and medication adherence 
[Bosworth et al., 2011; Ma & Lu, 2011]. As a result, improving the overall effectiveness of a 
therapy in a population will often necessitate identifying patient subpopulations for whom the 
therapy is likely to have limited effectiveness, and then utilizing alternative treatment strategies—
such as dosing or management changes, interventions designed to improve adherence, or even 
alternative therapies—in those patients. 
 
The role of prediction modeling in therapeutic effectiveness research. Because improving 
therapeutic effectiveness often requires identifying patient subpopulations in whom the therapy is 
generally more or less effective than would be expected in an idealized clinical trial scenario, 
prediction modeling is of vital importance to therapeutic effectiveness research. Clinical 
prediction models are most often based on regression methods, in which the outcome of 
interest—for instance, response to therapy or the development of side effects—is modeled as a 
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function of several predictor variables, in order to predict the probability of the outcome for a 
given individual. To be useful clinically, these models must be developed in a rigorous fashion 
and demonstrate generalizability, or the ability to perform well in the patient population of 
interest, not just the study cohort used to develop the model. Models are typically assessed both in 
terms of calibration, which refers to how well predicted probabilities match observed 
probabilities, and discrimination, which refers to how successful the model is at correctly ranking 
relatively lower and higher risk individuals. Additionally, model generalizability is typically 
assessed via external validation, in which the model is tested in a cohort of patients that were not 
used in the model development process. Finally, it is important to test whether use of the 
prediction model actually leads to better outcomes in practice. While observational studies can 
play an important role, testing of prediction model performance is most rigorously done through a 
randomized controlled trial, comparing outcomes on patients who have been randomized to 
receive therapy that has been tailored based on the results of prediction models to those who 
receive standard therapy without prediction. Examples include clinical trials of whether 
pharmacogenetic dosing algorithms for warfarin led to improvement in anticoagulation control 
over clinical dosing algorithms or standard clinical practice [Kimmel et al., 2013; Pirmohamed et 
al., 2013]. Special attention should be paid in such trials to the generalizability of the study 
population, since effectiveness, not efficacy, is the metric of interest. Furthermore, the time and 
monetary costs of conducting such trials can often be prohibitive, especially considering that 
model performance can deteriorate over time, requiring recalibration. 
 
Warfarin is a common oral anticoagulant that has served as a model for therapeutic effectiveness 
research. Warfarin sodium is a commonly prescribed anticoagulant used for the primary and 
secondary prevention of thromboembolic disease, and until recently, it was the only available oral 
anticoagulant in the US [Mohapatra, Tran, Gore, & Spencer, 2005]. The drug has been used in 
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practice for 60 years; however, it remains difficult to use because of an unusually narrow 
therapeutic range and as much as a 30-fold variability in dosing requirements for patients to 
achieve stable therapeutic levels of anticoagulation [Wadelius et al., 2004]. Over-anticoagulation 
from having too high a dose of warfarin can result in life-threatening bleeding complications, 
such as intracranial hemorrhage, while under-anticoagulation from having too low a dose of 
warfarin reduces the efficacy of the therapy, leaving patients at risk for strokes and other 
thromboembolic events [Higashi et al., 2002; Sconce et al., 2005; White et al., 1987]. Even non-
serious adverse events such as minor bleeding can lead to warfarin discontinuation [Gullov, 
Koefoed, & Petersen, 1999]. As a result of these limitations, much research has been devoted to 
improving the effectiveness of warfarin therapy in practice. Most of this research has focused on 
the development of models to predict a patient’s required warfarin dose, with the idea that 
knowing the required therapeutic dose in advance will make it easier to titrate a given patient to a 
therapeutic level when starting therapy [Gage et al., 2008; Klein et al., 2009]. Pharmacogenetic 
dosing models for warfarin are typically able to predict within 20% of patients’ actual therapeutic 
dose in about half of individuals [Finkelman, Gage, Johnson, Brensinger, & Kimmel, 2011], 
although their accuracy has historically been much lower in African Americans [Klein et al., 
2009; Limdi et al., 2008; Schelleman, Chen, et al., 2008; Suarez-Kurtz & Botton, 2013]. 
 
Current dosing strategies for warfarin often result in a lengthy and dangerous dose titration 
period. Despite the availability of dosing algorithms, warfarin is still typically dosed empirically, 
with patients started at the population average dose of 5mg/day and then titrated either up or 
down based on changes in the international normalized ratio (INR) [Fihn et al., 1993]. As a result, 
patients often experience a lengthy dose titration period of weeks to months at the onset of 
warfarin therapy, during which time they are at particularly high risk of complications from 
improper anticoagulation levels. For instance, it has been estimated that bleeding risk is 
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approximately 2-6 times higher during the first 3 months of warfarin therapy, and the rate of 
thromboembolic events has been shown to be elevated very early in a patient’s course of warfarin 
therapy in some contexts, such as following surgery [Brotman, Jaffer, Hurbanek, & Morra, 2004; 
Fihn et al., 1993]. In addition, a prolonged dose titration phase substantially increases patient 
burden by increasing the frequency of required visits for INR monitoring for an extended period 
of time. As a result, such patients may have increased medical costs, reduced quality of life 
[Dantas, Thompson, Manson, Tracy, & Upshur, 2004], greater dissatisfaction, and higher rates of 
warfarin discontinuation [Arnsten, Gelfand, & Singer, 1997; Fang et al., 2010], thus depriving 
these patients of the benefit of a highly efficacious therapy. 
 
Patients at high risk of having a lengthy dose titration period on warfarin therapy may be more 
appropriately treated with alternative oral anticoagulation agents. In 2010, the FDA approved 
dabigatran, a direct thrombin inhibitor, for patients with non-valvular atrial fibrillation. Thus, 
dabigatran became the first oral anticoagulant to be approved in the U.S. since the introduction of 
warfarin. Rivaroxaban, a Factor Xa inhibitor, was approved by the FDA in November 2011, and 
another Factor Xa inhibitor, apixaban, was recently approved by the FDA in December 2012. 
Both dabigatran and rivaroxaban have been shown to be non-inferior to warfarin for prevention of 
thromboembolic events [Connolly et al., 2009; Patel et al., 2011], while apixaban was shown to 
be superior to warfarin for stroke prevention in the setting of a randomized trial [Granger et al., 
2011]. Bleeding rates were also generally low and either comparable to or lower than warfarin 
[Siegal & Crowther, 2013]. Moreover, these alternative agents all have the advantage of having 
much less variability in their dosing requirement for patients [Cove & Hylek, 2013]—although 
recent evidence suggests that at least dabigatran may have more dosing variability than had been 
previously thought [Charlton & Redberg, 2014; Cohen, 2014a, 2014b; Moore, Cohen, & 
Mattison, 2014]—allowing for fixed dosing regimens and eliminating the monitoring burden of 
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anticoagulation. Furthermore, these newer agents also have fewer food and drug interactions, 
meaning that they might necessitate fewer lifestyle adjustments and be less prone to fluctuations 
in anticoagulation levels over the long term. 
 
However, the newer agents have some issues that have prevented them from completely replacing 
warfarin in clinical practice. All of the drugs are substantially more expensive, as annual direct 
pill costs for the newer agents are about 60 times more expensive than warfarin [Avorn, 2011]. 
Furthermore, more of the cost of the newer agents are shifted to patients, since co-pays on the 
expensive new medications are generally much higher than co-pays for the laboratory testing 
required with warfarin [Avorn, 2011]. Additionally, dabigatran has shown problems of frequent 
gastrointestinal side effects and appears to have an increased risk of myocardial infarction relative 
to warfarin [Ansell, 2010; Uchino & Hernandez, 2012], while rivaroxaban may have an increased 
risk of spinal hematoma [Jaeger, Jeanneret, & Schaeren, 2011; Steffel & Braunwald, 2011]. 
Furthermore, it is too soon to know what the full risk profile for apixaban might be in real-world 
clinical practice.  
 
Ironically, many clinicians have been made uncomfortable by the inability to monitor 
anticoagulation level in individual patients on the alternative agents. With warfarin, monitoring 
allowed physicians the opportunity to tailor therapy to those, for example, with increased 
bleeding risk or renal dysfunction; to identify and potentially address problems with therapy 
before they led to bleeding or thrombotic events; and to determine whether events that did occur 
were due to non-therapeutic drug levels [Ansell, 2010]. Removing the frequent contact with 
health care providers that comes with monitoring might also worsen adherence to the newer 
anticoagulants [Cutler et al., 2014], and poor adherence could theoretically increase the risk of 
adverse outcomes for patients on the newer anticoagulants relative to those on warfarin, due to 
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the shorter half-lives of the newer drugs [Ansell, 2010]. The lack of an antidote to the alternative 
agents has also led to concern about an inability to stop anticoagulation for patients who develop 
serious bleeding [Steffel & Braunwald, 2011], including those who are victims of trauma [Cotton, 
McCarthy, & Holcomb, 2011]; thus, development of antidotes is an active area of current 
research [Lu et al., 2013]. As a result of all of these issues, there is uncertainty in the clinical 
community about when to use these newer anticoagulants instead of warfarin [Ansell, 2010; 
Hankey & Eikelboom, 2010; Kanagasabapathy, Chowdary, & Gatt, 2011; Mangiafico & 
Mangiafico, 2012]. 
 
Our research is motivated by the hypothesis that individual patients who are likely to respond 
poorly to warfarin could potentially be better treated with less burdensome but more expensive 
alternative oral anticoagulants, though we will not formally address this specific hypothesis in 
this dissertation. Recent research has suggested that the cost-effectiveness of dabigatran relative 
to warfarin is greatest when used in patients who would have had poor INR control on warfarin 
[Freeman et al., 2011; Shah & Gage, 2011], and there is no reason to expect that this would be 
different for rivaroxaban and apixaban. Thus, predicting warfarin response in individual patients 
prior to initiating anticoagulation therapy may be an optimal and cost-effective approach to 
incorporating alternative oral anticoagulants alongside warfarin in clinical practice. 
 
Existing research is inadequate for identifying patients at high risk of prolonged dose titration on 
warfarin therapy. While there has been extensive research to determine the factors that affect 
required therapeutic maintenance dose [Gage et al., 2008, 2004; Kimmel et al., 2008; Klein et al., 
2009; Lenzini et al., 2010; Rieder et al., 2005; Schelleman et al., 2010; Schelleman, Chen, et al., 
2008; Schelleman, Limdi, & Kimmel, 2008; Voora et al., 2005], much less is known about the 
factors that lead to a prolonged dose titration phase for patients starting warfarin. Some evidence 
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suggests that genetic variants associated with maintenance dose may also be associated with 
prolongation of the dose titration period. For instance, the APOE ε3 allele has been associated 
with delay of reaching maintenance dose in African Americans [Cavallari et al., 2011]. Mutations 
in CYP2C9 have also been associated with increased time to maintenance dose [Higashi et al., 
2002; Meckley, Wittkowsky, Rieder, Rettie, & Veenstra, 2008], and variants in VKORC1 have 
been associated with increased time to first therapeutic INR [Schwarz et al., 2008], although the 
results for these variants have been mixed [Limdi et al., 2008]. Variants in these genes have also 
been associated with more frequent dosing changes and greater time spent out of therapeutic INR 
range [Limdi, Wiener, Goldstein, Acton, & Beasley, 2009; Schwarz et al., 2008]. However, 
factors that are associated with outcomes in population studies often perform poorly when 
predicting future outcomes in individuals [Pepe, Janes, Longton, Leisenring, & Newcomb, 2004]. 
Thus, it is essential to directly test whether these genetic variants could be clinically useful for 
predicting a prolonged dose titration period in individual patients at the onset of therapy. 
 
Furthermore, given the multifactorial nature of warfarin response, it seems implausible that 
genetic variants are the only important predictors of a prolonged dose titration phase. However, 
potentially important clinical and sociodemographic factors have not, to our knowledge, been 
studied in this context. There is indirect evidence, though, including results from our group, that 
poor adherence to warfarin could lead to prolongation of the dose titration period, as it has been 
associated with significantly worse anticoagulation control [Cavallari et al., 2009; Kimmel et al., 
2007]. Additionally, we and others have shown that baseline clinical and sociodemographic 
factors—such as younger age, greater than high school education, current employment, and 
cognitive impairment—are associated with subsequent poor warfarin adherence [Arnsten et al., 
1997; Platt et al., 2008], as has been seen with other medications [Ediger et al., 2007; Kulkarni, 
Alexander, Lytle, Heiss, & Peterson, 2006; Nikolaus et al., 1996]. However, these prediction 
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models have not shown very good discrimination in individual warfarin patients [Platt et al., 
2010]. Finally, a variety of social and clinical factors have been associated with several other 
endpoints that may be related to a prolonged dose titration phase, including time in therapeutic 
INR range, risk of bleeding events, and discontinuation of warfarin therapy [Beyth, Quinn, & 
Landefeld, 1998; Fang et al., 2010; Gage et al., 2006; Lip, Frison, Halperin, & Lane, 2011; 
Shireman et al., 2006]. 
 
In this dissertation, we aim to improve our ability to predict prolonged dose titration on warfarin 
therapy as well as better understand its causes. When beginning this research, we hypothesized 
that baseline clinical, genetic, and social factors could predict prolonged dose titration, which we 
define as failure to reach stable therapeutic maintenance dose within 3 months of initiating 
warfarin therapy. In Chapter 2, we focus on identifying both baseline and post-initiation factors 
that are associated with time to the achievement of maintenance dose. Better knowledge of which 
factors lead to a longer time to maintenance dose could help clinicians identify patients who are at 
high risk of prolonged dose titration. Moreover, knowledge of reversible factors that are 
associated with prolonged dose titration, such as behavioral factors, could potentially even 
provide targets for interventions designed to improve anticoagulation control in patients on 
warfarin. In Chapter 3, we focus on developing and externally validating a prediction model for 
prolonged dose titration when starting warfarin therapy. Accurate prediction of prolonged dose 
titration could help clinicians decide when to use alternative strategies for anticoagulation, such 
as less burdensome but more expensive alternative oral anticoagulants, genetic testing to try to 
improve dosing on warfarin, or more frequent INR monitoring. 
 
Prediction models for individual response to warfarin therapy will need to be able to generalize 
across a wide variety of clinical settings to maximize their clinical utility. There are over 30 
9 
 
million prescriptions for warfarin in the U.S. every year, with common indications including 
stroke prophylaxis in atrial fibrillation, the presence of a mechanical heart valve, and treatment 
for thromboembolic disease [Wysowski, Nourjah, & Swartz, 2007]. Patients on warfarin are 
managed by specialty anticoagulation clinics, primary care physicians, cardiologists, 
hematologists, and pharmacists, among others. As a result, it is likely that prediction models 
developed in one clinical setting may not perform well in other settings, which could diminish 
their overall usefulness in clinical practice. Deterioration of prediction model performance across 
different clinical settings is an example of poor model transportability, which is a component of 
model generalizability that refers to a model’s ability to produce accurate and reliable predictions 
in different populations from the one in which the model was derived [Justice, Covinsky, & 
Berlin, 1999]. Ultimately, the transportability of a prediction model can only be assessed using 
validation data from distinct populations. 
 
Utility of clinical prediction models is hampered by concerns about poor transportability across 
broad areas of clinical medicine. The problem of poor transportability of prediction models is 
much broader than just predicting warfarin response. For instance, the American Heart 
Association (AHA) and the American College of Cardiology’s (ACC) most recent cholesterol 
management guidelines were largely dependent on an individual’s predicted 10-year risk of 
cardiovascular events [Stone et al., 2014]. However, the prediction models used in these 
guidelines have been criticized because of concerns that they over-predict the risk of 
cardiovascular disease in cohorts other than those used to develop the prediction model [Ridker & 
Cook, 2013]. Additionally, there are several documented examples of validated prediction models 
failing to generalize to different populations. For example, the EuroSCORE model, which was 
developed in European populations to predict 30-day mortality in patients undergoing cardiac 
surgery, failed to generalize to Australian surgical patients [Yap et al., 2006]. In another example, 
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a clinical prediction rule for predicting deep vein thrombosis (DVT) performed well in the 
secondary referral patient population in which it was developed, but failed to generalize to a 
primary care setting [Oudega, Hoes, & Moons, 2005]. Furthermore, this problem is likely even 
more widespread because of the many clinical outcomes that are known to vary substantially 
across clinical sites, including readmission after hospitalization for heart failure [Ross et al., 
2008], mortality following surgery for colorectal cancer [Schootman et al., 2014], false-positive 
results from mammographic screening [Roman, Skaane, & Hofvind, 2014], graft failure after 
liver transplantation [Asrani et al., 2013], and medication adherence rates among diabetes patients 
[Sherman, Sekili, Prakash, & Rausch, 2011]. As a result, methods to improve prediction model 
transportability could be expected to impact a wide range of areas in clinical medicine, and could 
be especially transformative for therapeutic effectiveness research. 
 
Methods to improve prediction model transportability. Poor transportability of a prediction model 
often occurs because of a problem of underfitting rather than overfitting [Justice et al., 1999]. In 
other words, important predictors are either unknown, misspecified, or excluded from the original 
model, and model performance degrades when tested in new populations with a different 
conditional prevalence of those predictors. As a result, it can be very difficult to find statistical 
solutions to problems of transportability using the derivation sample, because by definition, the 
model needs to be tested on a sample with a different empirical distribution from the derivation 
sample in order to determine its transportability. Thus, established methods such as Bayesian 
model averaging [Hoeting, Madigan, Raftery, & Volinsky, 1999], bootstrap aggregation or 
bagging [Breiman, 1996], and cross-validation [Borra & Di Ciaccio, 2010], which are effective at 
reducing model overfitting, would not necessarily be expected to lead to improvements in model 
transportability. 
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In Chapter 4, we examine sequential model updating of mixed-effects models as a potential 
strategy for improving prediction model transportability. In this approach, predictions are made 
on individuals using the best available model at that time. Then, when their outcome data 
becomes available, the model is re-estimated incorporating the newly available data. In short, 
sequential model updating solves the problem of derivation datasets not being representative of 
the population of interest by incorporating data from the population of interest into the derivation 
dataset over time. In practice, sequential model updating would likely involve integrating the 
prediction model into an electronic health records system (EHR) that spans multiple clinical sites. 
Predictions for specific patients could be made using data already available in the EHR, and 
outcomes would be automatically captured as they occur. This scheme would have the advantage 
of automatically calibrating to local conditions, thus improving the transportability of the model, 
without the need to recruit additional cohorts for constructing and validating separate prediction 
models at each individual site. Our research attempts to quantify these potential gains in 
prediction accuracy, as well as the types of scenarios where they might be expected to work best. 
The results of this research could potentially enable future prediction models to be more reliable 
in real-world clinical practice, both for oral anticoagulation research and for therapeutic 
effectiveness research in general. 
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CHAPTER 2. FACTORS AFFECTING TIME TO MAINTENANCE DOSE 
IN PATIENTS INITIATING WARFARIN 
 
Brian S Finkelman, Benjamin French, Luanne Bershaw, and Stephen E Kimmel 
 
 
ABSTRACT 
Background. Patients starting warfarin often experience lengthy dose-titration periods, when they 
are at high risk for bleeding and thromboembolism. However, relatively little is known about why 
some patients take longer than others to reach maintenance dose. Thus, we sought to identify 
social, clinical, and genetic factors associated with prolonged time to maintenance dose (TTM). 
 
Methods. We conducted a time-to-event analysis, using a prospective cohort of patients initiating 
warfarin (N = 390). Additionally, we examined whether changes in post-initiation factors were 
associated with TTM. Finally, we performed a secondary analysis in a subcohort (N = 156) 
assessing the effect of adherence on TTM. 
 
Results. No genetic or post-initiation factors were significantly associated with TTM. However, 
previous use of warfarin (HR = 0.64; 95% CI 0.46, 0.88), current smoking status (HR = 0.61; 
95% CI 0.39, 0.96), fewer than 4 doctor’s visits in the previous year (HR = 0.63 vs 4-12 visits; 
95% CI 0.46, 0.88), and worse general health status (HR = 0.63; 95% CI 0.47, 0.84) were 
significantly associated with longer TTM. Use of illegal injectable drugs (HR = 2.51; 95% CI 
1.17, 5.39) was associated with shorter TTM. On secondary analysis, the hazard ratio for better 
adherence and TTM was 1.70 (95% CI 0.88, 3.27). 
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Conclusions. Pre-existing behavioral factors, health care utilization, and health quality were 
associated with TTM in patients initiating warfarin, but clinical comorbidities and genetic factors 
were not. Future studies are needed to determine whether warfarin patients with prolonged TTM 
would have better outcomes on alternative agents. 
 
BACKGROUND 
Patients initiating warfarin often experience lengthy dose-titration periods of weeks to months, 
during which time they are at particularly high risk of both bleeding and thromboembolic 
complications from improper anticoagulation levels [Fihn et al., 1993; Hylek, Skates, Sheehan, & 
Singer, 1996]. Additionally, during the dose-titration phase, patients may have their international 
normalized ratio (INR) monitored as frequently as 1-2 times per week, while INR monitoring 
during the maintenance phase of therapy is generally only once every 1-2 months. As a result of 
this substantial increase in monitoring burden, patients with a long time to maintenance dose 
(TTM) may have increased medical costs, reduced quality of life [Dantas et al., 2004], greater 
dissatisfaction, and higher rates of warfarin discontinuation [Arnsten et al., 1997; Fang et al., 
2010]. Furthermore, given the recent availability of alternative oral anticoagulants—including 
dabigatran, rivaroxiban, and apixaban—a better understanding of the causes of prolonged TTM in 
warfarin therapy is of increasing importance, because it could potentially help identify patient 
subsets who might be better treated with alternative agents that, while more costly, do not require 
monitoring of drug or anticoagulation levels. 
 
In contrast to the large amount of research that has been done on the genetic and clinical factors 
relating to warfarin maintenance dose requirement [Lee & Klein, 2013], relatively little is 
understood about the factors that lead to a longer TTM. Previous research on the association 
between genetic variants and TTM has been mixed [Cavallari et al., 2011; Higashi et al., 2002; 
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Jorgensen et al., 2009; Limdi et al., 2008; Meckley et al., 2008], with few studies conducted in 
prospective cohorts. Given the multifactorial nature of warfarin response, however, it seems 
implausible that genetic variants are the only important factors associated with TTM. Indeed, a 
variety of non-genetic factors, including social and clinical factors, have been associated with 
several other endpoints that may be related to prolonged TTM, including poor warfarin adherence 
[Cavallari et al., 2009; Kimmel et al., 2007], time in therapeutic INR range [Apostolakis, 
Sullivan, Olshansky, & Lip, 2013; Witt et al., 2009], and risk of bleeding events [Beyth et al., 
1998; Gage et al., 2006; Lip et al., 2011; Shireman et al., 2006]. However, such factors have not, 
to our knowledge, been rigorously studied in the specific context of TTM. 
  
We sought to examine the association between social, clinical, and genetic factors and TTM for 
patients initiating warfarin. Additionally, we aimed to identify whether changes in factors after 
warfarin initiation could lead to increased TTM. Identifying such factors could help identify 
patient subsets that might be better treated with warfarin versus one of the newer anticoagulants. 
To accomplish these aims, we conducted a time-to-event analysis of the INR Adherence and 
Genetics (IN-RANGE) cohort, a large prospective cohort of adults initiating warfarin [Kimmel et 
al., 2007; Platt et al., 2008]. 
 
METHODS 
IN-RANGE cohort. The IN-RANGE cohort of warfarin patients has been used to study the 
clinical and genetic predictors of warfarin maintenance dose and adherence [Kealey et al., 2007; 
Kimmel et al., 2007, 2008; Parker et al., 2007; Platt et al., 2008, 2010; Schelleman et al., 2010, 
2007; Schelleman, Chen, et al., 2008]. Participants were recruited from specialty anticoagulation 
clinics at the Hospital of the University of Pennsylvania (HUP), the Philadelphia Veterans Affairs 
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Medical Center (PVAMC), and Hershey Medical Center. Institutional review board approval was 
obtained at all three sites, and all study participants provided written informed consent. Exclusion 
criteria included being under 21 years old, being unwilling or unable to provide consent, having 
an abnormal INR prior to starting warfarin or heparin therapy, or the presence of antiphospholipid 
antibodies. Participants were enrolled between April 2002 and February 2006. All participants in 
the original IN-RANGE cohort (N = 390) were eligible for inclusion in the current study. 
 
Primary outcome. The primary outcome was the time from warfarin initiation to the first 
maintenance dose-defining visit, in days. Patients were considered to have achieved maintenance 
dose if they had three consecutive INRs within the target therapeutic range, with no constraint on 
the amount of time between INRs. This definition was prespecified prior to cohort enrollment. 
Having a longer TTM is generally worse for patients because of increases in bleeding and 
thrombosis risk as well as patient burden. TTM was a secondary outcome of the original IN-
RANGE study; however, a priori power calculations demonstrated adequate power to detect 
clinically meaningful hazard ratios (Table 2.1). 
 
Exposures. A total of 38 pre-existing, or ‘baseline,’ variables were considered for analysis. These 
included social, clinical, and genetic factors, which were all assessed at the time of recruitment 
(Tables 2.2 and 2.3). Genetic factors studied were the VKORC1 -1639G>A variant (rs9923231), 
the CYP2C9*2 and CYP2C9*3 variants (rs1799853 and rs1057910, respectively), and the APOE 
ε2 and ε4 alleles (based on the rs7412 and rs429358 variants, respectively). As described 
previously [Kimmel et al., 2008], DNA was extracted from buccal swab preparations and 
analyzed using PCR amplification by collaborators who were blinded to patient characteristics 
and outcomes. All non-genetic factors were ascertained via self-report, making the data 
comparable to what would be available to clinicians managing warfarin patients.  
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Table 2.1. Power calculation for primary analysis 
Table 2.2. Baseline social and genetic factors considered as candidate variables for primary analysis and 
their specifications. 
 
  
Percent Exposed Minimum Detectable  
Hazard Ratio > 1 
Maximum Detectable 
Hazard Ratio < 1 
50% 1.4 0.71 
35% 1.4 0.71 
25% 1.5 0.67 
15% 1.6 0.63 
10% 1.7 0.59 
Calculations are based on a type I error rate of 0.05, 300 subjects 
reaching maintenance dose, and 80% power. Calculations were 
performed using PASS 11. 
Factor Specification 
Social  
Self-reported race Binary (0 = not African American; 1 = African American) 
Gender Binary (0 = male; 1 = female) 
Marital status Categorical (1 = married (ref); 2 = separated/divorced;  
3 = widowed; 4 = never married) 
Employment status Categorical (1 = working; 2 = unemployed; 3 = retired (ref); 
4 = disabled) 
Education status Binary (0 = more than high school; 1 = high school or less) 
Annual income per household 
member 
Categorical (1 = < $15,000; 2 = $15,000 to $20,000;  
3 = > $20,000 (ref)) 
Insurance status Categorical (1 = private (ref); 2 = any VA; 3 = Medicaid; 4 = 
Medicare only; 5 = no insurance) 
Ever used illegal injectable drugs Binary (0 = no; 1 = yes) 
Number of alcoholic drinks per 
week 
Binary (0 = 0–7 drinks; 1 = more than 7 drinks) 
Current smoking status Binary (0 = not current smoker; 1 = current smoker) 
Self-reported general health status Binary (0 = excellent/very good/good; 1 = fair/poor) 
No. hospitalizations in past 12 
months 
Continuous (linear) 
No. doctor’s visits in past 12 
months 
Categorical (1 = 0–3  visits; 2 = 4–12 visits (ref);  
3  = 13 or more visits) 
Had difficulty receiving health 
care in the past 12 months 
Binary (0 = no; 1 = yes) 
  
Genetic  
VKORC1 -1639G>A variant  Binary (0 = no variants; 1 = at least one variant) 
CYP2C9*2 and CYP2C9*3 
variants 
Binary (0 = no variants; 1 = at least one variant) 
APOE ε2 allele Binary (0 = no copies; 1 = at least one copy) 
APOE ε4 allele Binary (0 = no copies; 1 = at least one copy) 
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Table 2.3. Baseline clinical factors considered as candidate variables for primary analysis and their 
specifications. 
 
Additionally, several ‘post-initiation’ factors were studied, including changes in the use of 
interacting medications, quantitative and qualitative changes in diet, changes in weight, and 
changes in alcohol consumption since starting warfarin. Changes in interacting medications were 
defined as starting or stopping an interacting medication after warfarin initiation; the list of 
potentially interacting medications is shown in the Appendix. Finally, warfarin adherence, 
measured by medication event monitoring system (MEMS) caps [Kimmel et al., 2007], was 
considered in a secondary analysis because adherence data were only available in 40% of the 
cohort (N = 156). Some patients did not have MEMS cap data because the devices first became 
available after enrollment had begun, while others were offered to use the device but declined. 
 
Factor Specification 
Clinical  
Age (years) at baseline visit Continuous (linear) 
Body Mass Index Continuous (linear) 
Previous use of warfarin Binary (0 =  no; 1 = yes) 
Warfarin indication Categorical (1 = atrial fibrillation/atrial flutter (ref);  
2 = post deep vein thrombosis/pulmonary embolism;  
3 = dilated cardiomyopathy/left ventricular thrombosis;  
4 = stroke/transient ischemic attack; 5 = other)  
Number of interacting 
medications being used at baseline 
Binary (0 = 0–1 medications; 1 = 2 or more medications) 
Amiodarone use at baseline Binary (0 =  no; 1 = yes) 
Statin use at baseline Binary (0 =  no; 1 = yes) 
CHADS2 score Categorical (1 = 0 (ref); 2 = 1; 3 = 2 or higher) 
History of pulmonary embolism Binary (0 =  no; 1 = yes) 
History of deep vein thrombosis Binary (0 =  no; 1 = yes) 
History of peptic ulcer disease Binary (0 =  no; 1 = yes) 
History of gastritis Binary (0 =  no; 1 = yes) 
History of stroke Binary (0 =  no; 1 = yes) 
History of cancer Binary (0 =  no; 1 = yes) 
History of hypertension Binary (0 =  no; 1 = yes) 
History of diabetes Binary (0 =  no; 1 = yes) 
History of arrhythmia Binary (0 =  no; 1 = yes) 
History of congestive heart failure Binary (0 =  no; 1 = yes) 
History of myocardial infarction Binary (0 =  no; 1 = yes) 
History of any other heart disease Binary (0 =  no; 1 = yes) 
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Primary Analysis. Cox regression models, stratified by clinical site, were used for all analyses. 
Variable selection for the primary model of baseline factors was performed using a combination 
forward-backward algorithm. Specifically, univariable analyses were performed on baseline 
candidate variables, and those with P < 0.2 via the likelihood ratio test were included in the full 
model. The variable in the full model with the largest P-value via the likelihood ratio test was 
successively removed until all P-values were less than 0.1. Next, all previously omitted variables 
were reintroduced one at a time. Those variables with P < 0.1 in this forward step were included 
in the final model, as were age and race, which were deemed clinically important. The variables 
included in the final model were age, race, previous use of warfarin, current smoking status, 
illegal injectable drug use, number of doctor’s visits in the previous year, general health status, 
history of arrhythmia, and having a variant in VKORC1. Complete-case analysis was used 
because only 32 individuals (9% of cohort) were missing data on any of these variables. 
 
To ensure that we could compare the effect of genetic factors with what has previously been 
observed in the literature, genetic factors were analyzed separately, adjusted for final model 
variables. Genetic factors were specified as binary variables, indicating whether at least one 
variant was present, in order to avoid data sparseness when assessing prespecified interactions 
between genotype and race. For the same reason, CYP2C9*2 and *3 variants were combined into 
a single binary variable. The effects of post-initiation factors, adjusted for final model variables, 
were also analyzed separately. All post-initiation factors were specified as time-dependent 
variables, with their value representing the total number of changes that an individual had 
experienced by a given date. Additionally, because of their time-dependent specification, models 
for post-initiation factors were adjusted for visit number to help prevent confounding by varying 
frequency of INR monitoring [Fihn et al., 1993].  
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Finally, because this study used the same cohort for variable selection and model estimation, 
there was concern about model overfitting and sensitivity to outliers. Thus, all reported point 
estimates, confidence intervals, and P-values in the primary analysis were estimated using 1,000 
bootstrap replications [Efron & Tibshirani, 1994]. Specifically, to perform the bootstrap 
procedure, individuals were repeatedly sampled with replacement, meaning that the same 
individuals could be selected multiple times in a given sample. The Cox model was then fit using 
this bootstrap sample, and hazard ratio estimates were recorded. This procedure was then 
repeated 1,000 times. Reported hazard ratio point estimates were calculated as the mean hazard 
ratio estimate from 1,000 bootstrap samples; confidence intervals and P-values were calculated 
based on the mean and variance of 1,000 bootstrap samples, assuming a normal distribution of the 
bootstrap samples. This method was chosen to improve the stability and interpretability of 
stratified estimates based on model interactions; however, use of quantiles from the empirical 
distribution for producing confidence intervals would have left the results for the main effects 
essentially unchanged (data not shown). These mean estimates are also slightly more stable than 
those using model-based estimates in the original sample. Additionally, confidence intervals and 
P-values are slightly more conservative than what would otherwise be observed. 
 
Secondary Analyses. Warfarin adherence was analyzed using the subcohort of patients with 
available MEMS cap data (N = 156), adjusting for final model variables. Adherence was 
specified as a time-dependent binary variable, indicating whether an individual had been ≥80% 
adherent over the past three visits. Age was excluded from adjusted adherence models to reduce 
the potential bias from adjustment of near-instruments [Myers et al., 2011; Pearl, 2011], because 
it is known to be a strong predictor of warfarin adherence [Platt et al., 2008, 2010], while not 
being associated with the outcome. Use of illegal injectable drugs was also excluded because of 
unstable estimates due to data sparseness in the subcohort. Finally, we performed a secondary 
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analysis examining whether individuals with high (≥49 mg/wk) or low (≤21 mg/wk) maintenance 
dose had increased TTM. As in the primary analysis, point estimates, confidence intervals, and P-
values for all secondary analyses were based on 1,000 bootstrap replications. 
 
Sensitivity Analyses. We conducted a sensitivity analysis using inverse probability of censoring 
weights to determine the potential impact of informative censoring on our results [Cain & Cole, 
2009; Robins & Finkelstein, 2000]. In this analysis, a Cox model was constructed with time until 
censoring, rather than TTM, as the outcome of interest. All candidate baseline variables, post-
initiation variables, adherence, visit number, INR, and warfarin dose were considered for 
inclusion in the model. Factor variables with >1% missingness were given missing indicators, as 
well, because missing data were felt to be potentially predictive of censoring. Variables were 
selected using an analogous combination forward-backward algorithm, with less restrictive 
criteria of P < 0.25 for entry and retention. This model was then used to predict individual 
probabilities of censoring at each patient-visit, which could then be used to construct inverse 
probability weights, using the formula:  
   {
                                              ( )   
  ( ( )   )
  ( ( )   | ( ))
  ( )   
 
for which wt indicates the weight for a patient at time t, C(t) indicates whether an individual was 
censored at time t, and X(t) indicates an individual’s covariates, time-varying or otherwise, at 
time t. These weights were then applied to the final model in the primary analysis to see how 
much incorporation of the weights changed the original hazard ratio estimates. 
 
A sensitivity analysis was also performed treating visit number, rather than days, as the unit of 
time for the primary analysis, in order to look at the impact of potentially variable visit 
frequencies on our results. Additionally, we performed a sensitivity analysis where standard, non-
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bootstrapped model-based estimates were calculated. Finally, the individual effects of CYP2C9*2 
and CYP2C9*3, as well as using an additive specification (i.e. 0, 1, or 2) for all genetic variants, 
were assessed in a sensitivity analysis. All analyses were performed using R 3.0.2 [R 
Development Core Team, 2014]. 
 
RESULTS 
There were 390 subjects in the cohort, whose characteristics are shown in Table 2.4. Median 
TTM was 45 days (IQR 15, 135), with 288 subjects (74%) achieving maintenance dose by the 
end of the study. Median number of visits required to achieve maintenance dose was 7 (IQR 4, 
13). Genotype frequencies by race are shown in Table 2.5. 
 
The results for the final model are shown in Table 2.6. Complete data on all variables in the final 
model were available in 358 subjects (91%), with 267 (75%) achieving maintenance dose by the 
end of the study. Note that because this is a time-to-event analysis where the “event” is reaching 
maintenance dose, hazard ratios below 1 indicate that a factor is associated with longer TTM and 
is worse for patients, on average. This is in contrast to most studies where the event of interest is 
harmful (i.e. mortality), and hazard ratios below 1 would be considered protective. Previous use 
of warfarin (HR = 0.64 vs no previous use of warfarin; 95% CI 0.46, 0.88), current smoking 
status (HR = 0.61 vs current non-smoking status; 95% CI 0.39, 0.96), having fewer than 4 
doctor’s visits in the previous year (HR = 0.63 vs 4-12 visits; 95% CI 0.46, 0.88), and having 
fair/poor general health status (HR = 0.63 vs excellent/very good/good general health; 95% CI 
0.47, 0.84) were significantly associated with longer TTM. In contrast, use of illegal injectable 
drugs (HR = 2.51 vs no reported drug use; 95% CI 1.17, 5.39) was associated with shorter TTM.   
22 
 
Table 2.4. Characteristics of the IN-RANGE clinical cohort (N = 390). 
 
  
Characteristic 
N (%) or 
Mean (SD) 
Characteristic 
N (%) or 
Mean (SD) 
Age (years) 59.2 (15.0) CYP2C9 genotype:  
Female gender 119 (31) *1*1 283 (76) 
Race:  *1*2 59 (16) 
African American 174 (45) *1*3 26 (7) 
Caucasian 206 (53) *2*3 3 (1) 
Other 10 (3) VKORC1 -1639G>A genotype:  
Body Mass Index:  GG 209 (56) 
< 25 122 (32) GA 149 (40) 
25–30 125 (32) AA 15 (4) 
> 30 140 (36) Insurance status:  
Warfarin indication:  Private 215 (56) 
Atrial fibrillation/flutter 188 (48) Any VA 107 (28) 
DVT/PE 116 (30) Medicaid 16 (4) 
DCM/LV thrombosis 26 (7) Medicare only 17 (4) 
Stroke/TIA 22 (6) None 29 (8) 
Other 38 (10) Employment status:  
Target INR 2–3 389 (99.7) Working 128 (33) 
Maintenance dose (mg/wk) 39.9 (22.0) Unemployed 34 (9) 
Previous use of warfarin 96 (25) Retired 143 (37) 
History of hypertension 192 (49) Disabled 81 (21) 
History of diabetes 107 (27) Income per household member:  
History of PUD 36 (9) < $15,000/year 109 (33) 
History of CHF 78 (20) $15,000–$20,000/year 99 (30) 
> 1 Interacting medications 210 (54) > $20,000/year 122 (37) 
Smoking status:  AC clinic site:  
Never smoked 141 (36) HUP 184 (47) 
Past smoker 185 (47) PVAMC 137 (35) 
Current smoker 64 (16) Hershey 69 (18) 
Abbreviations:anticoagulation (AC), congestive heart failure (CHF), deep vein thrombosis 
(DVT), dilated cardiomyopathy (DCM), Hospital of the University of Pennsylvania (HUP), left 
ventricular (LV), peptic ulcer disease (PUD), Philadelphia Veterans Administration Medical 
Center (PVAMC), pulmonary embolism (PE), and transient ischemic attack (TIA). 
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Table 2.5. Frequencies of VKORC1, CYP2C9, and APOE genotypes stratified by race. 
 
  
Genotype Not African American  
N (%)a 
African American  
N (%)a 
VKORC1 -1639G>A   
GG 73 (36) 136 (80) 
GA 116 (57) 33 (20) 
AA 15 (7.4) 0 (0.0) 
CYP2C9   
*1*1 128 (63) 155 (92) 
*1*2 47 (23) 12 (7.1) 
*1*3 25 (12) 1 (0.6) 
*2*3 3 (1.5) 0 (0.0) 
APOE   
ε2/ε2 1 (0.5) 4 (2.4) 
ε2/ε3 25 (12) 22 (13) 
ε2/ε4 3 (1.5) 11 (6.5) 
ε3/ε3 131 (64) 80 (47) 
ε3/ε4 45 (22) 46 (27) 
ε4/ε4 1 (0.5) 7 (4.1) 
aPercents are rounded to the nearest percent for values ≥10% and to the 
nearest tenth of a percent for values below that cut-off. As a result, 
percents may not appear to add up to exactly 100%. 
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Table 2.6. Unadjusted and adjusted hazard ratios for time to maintenance dose for variables included in the 
final model. 
 
 
There was evidence to suggest that the proportional hazards assumption may be violated for our 
primary analysis (P = 0.01), but inspection of survival curves for individual covariates indicated 
Baseline Factora 
(N = 358)b 
N (%) or  
Mean (SD) 
Unadjustedc Adjustedc 
Hazard Ratiod P-valuee Hazard Ratiod P-valuee 
Age (years) 59 (15) 1.01 (1.00, 1.01) 0.24 1.01 (1.00, 1.02) 0.15 
Race      
African American 159 (44) 0.85 (0.65, 1.11) 0.24 1.02 (0.73, 1.42) 0.90 
Caucasian or other 199 (56) —  —  
Previous use of warfarin      
Yes 89 (25) 0.69 (0.52, 0.93) 0.015 0.64 (0.46, 0.88) 0.007 
No 269 (75) —  —  
Current smoking status      
Yes 61 (17) 0.72 (0.47, 1.09) 0.12 0.61 (0.39, 0.96) 0.031 
No 297 (83) —  —  
Self-reported illegal 
injectable drug use 
     
Yes 17 (5) 1.65 (0.73, 3.73) 0.23 2.51 (1.17, 5.39) 0.018 
No 341 (95) —  —  
No. doctor’s visits in  
previous year: 
     
< 4 95 (27) 0.71 (0.52, 0.96) 0.085 0.63 (0.46, 0.88) 0.024 
4 – 12 174 (49) —  —  
> 12 89 (25) 0.86 (0.62, 1.20)  0.88 (0.61, 1.28)  
General health      
Fair/poor 114 (32) 0.66 (0.50, 0.88) 0.005 0.63 (0.47, 0.84) 0.002 
Excellent/very good/ 
good 
244 (68) —  —  
History of arrhythmia      
Yes 189 (53) 0.90 (0.70, 1.16) 0.43 0.79 (0.59, 1.05) 0.10 
No 169 (47) —  —  
No. variants in VKORC1      
≥1 159 (44) 1.23 (0.95, 1.59) 0.11 1.33 (0.99, 1.78) 0.061 
0 199 (56) —  —  
aAll non-genetic factors are based on self-report. 
bBoth unadjusted and adjusted results are from the same complete-case dataset to improve 
comparability. 
cAll models are stratified by anticoagulation clinic site. 
dHazard ratios and confidence intervals are based on the mean and variance from 1,000 bootstrap 
replications. Hazard ratios less than 1 indicate longer time to maintenance dose; hazard ratios greater 
than 1 indicate shorter time to maintenance dose. 
eAll P-values are based on the Wald test using the mean and variance of estimates from 1,000 bootstrap 
replications. Categorical variables were tested jointly. 
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that this should not have a qualitative effect on our results. The effects of genetic factors alone, 
stratified by race, are shown in Table 2.7. No genetic variant was significantly associated with 
TTM either before or after adjustment for covariates (All Pmain effect > 0.06), and no significant 
interactions between genetic variants and race were observed (All Pinteraction > 0.4). As shown in 
Table 2.8, no post-initiation factor was statistically significant either before or after adjustment 
for covariates (All P > 0.2). 
 
In secondary analyses, better adherence appeared significantly associated with shorter TTM in an 
unadjusted analysis (HR = 1.95; 95% CI 1.06, 3.59), but it was no longer significant after 
adjustment for covariates (HR = 1.70; 95% CI 0.88, 3.27), as shown in Table 2.9. By contrast, 
final maintenance dose was not significantly associated with TTM in either unadjusted [high dose 
HR = 1.03 (95% CI 0.79, 1.34); low dose HR = 1.13 (95% CI 0.78, 1.64); overall P = 0.81] or 
adjusted [high dose HR = 1.10 (95% CI 0.78, 1.54); low dose HR = 1.11 (95% CI 0.73, 1.69); 
overall P = 0.79] analyses. 
 
In sensitivity analyses, use of inverse probability of censoring weights did not appreciably change 
the results from those shown in Table 2.6, with a 3.3% mean change in hazard ratio estimates, as 
shown in Table 2.10. Additionally, use of visit number, rather than days, as the unit of time did 
not substantially change the results, with a 6.8% mean change in hazard ratio estimates (data not 
shown). Our results were also not substantially changed when standard, non-bootstrapped 
estimates were used, with a 1.1% mean change in hazard ratio estimates (data not shown). 
Finally, use of an additive specification for genetic variants and having separate variables for the 
CYP2C9*2 and CYP2C9*3 variants did not substantially change the results, with small 
quantitative changes toward the null (data not shown). 
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Table 2.7. Unadjusted and adjusted hazard ratios for time to maintenance dose for genetic factors, stratified 
by race. 
 
 
Table 2.8. Unadjusted and adjusted hazard ratios for time to maintenance dose for post-initiation factors. 
 
Genetic Variant 
(N = 358)a 
African 
American 
Unadjusted Adjustedd 
Hazard Ratiob Pinteraction
c Hazard Ratiob Pinteraction
c 
Any VKORC1 No 1.09 (0.81, 1.46) 0.42 1.31 (0.93, 1.85) 0.85 
 Yes 1.41 (0.78, 2.54)  1.40 (0.71, 2.77)  
Any CYP2C9 No 0.97 (0.69, 1.36) 0.99 1.05 (0.73, 1.52) 0.49 
 Yes 0.96 (0.53, 1.73)  0.68 (0.35, 1.35)  
Any APOE ε2 No 1.08 (0.68, 1.73) 0.93 0.91 (0.52, 1.58) 0.46 
 Yes 1.11 (0.62, 2.01)  1.21 (0.61, 2.40)  
Any APOE ε4 No 1.01 (0.71, 1.44) 0.93 0.97 (0.67, 1.42) 0.92 
 Yes 1.03 (0.57, 1.86)  1.00 (0.51, 1.98)  
aBoth unadjusted and adjusted results are from the same complete-case dataset to improve 
comparability. 
bHazard ratios and confidence intervals are based on the mean and variance from 1,000 bootstrap 
replications. Hazard ratios less than 1 indicate longer time to maintenance dose; hazard ratios 
greater than 1 indicate shorter time to maintenance dose. 
cP-values for interactions are based on the Wald test using the mean and variance of interaction 
terms from 1,000 bootstrap replications. 
dAdjusted for all baseline factors shown in Table 2.6. 
Post-Initiation  
Factor 
(N = 358)a 
Median time 
to first changeb  
Unadjusted Adjustede 
Hazard Ratioc P-valued Hazard Ratioc P-valued 
Change in interact- 
ing medication 
47 (28, 83) 0.93 (0.70, 1.24) 0.62 1.01 (0.76, 1.34) 0.95 
Change in diet:      
Qualitative 14 (7, 34) 0.97 (0.80, 1.17) 0.73 1.00 (0.82, 1.23) >0.99 
Quantitative 14 (7, 36) 0.91 (0.78, 1.07) 0.24 0.98 (0.84, 1.15) 0.82 
Change in weight 17 (7, 35) 0.93 (0.82, 1.06) 0.26 0.97 (0.83, 1.13) 0.70 
Change in alcohol  
use 
50 (29, 86) 0.86 (0.60, 1.23) 0.42 0.96 (0.68, 1.34) 0.80 
aBoth unadjusted and adjusted results are from the same complete-case dataset to improve 
comparability. 
bMedian time (IQR) in days from the initiation of warfarin to the first change experienced by an 
individual for the given variable. 
cHazard ratios are based on the mean estimate from 1,000 bootstrap replications. Hazard ratios less 
than 1 indicate longer time to maintenance dose; hazard ratios greater than 1 indicate shorter time to 
maintenance dose. 
dAll P-values are based on the Wald test using the mean and variance of estimates from 1,000 
bootstrap replications. Categorical variables were tested jointly. 
eAdjusted for all baseline factors shown in Table 2.6, plus visit number to prevent visit frequency from 
confounding the time-varying covariates. 
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Table 2.9. Unadjusted and adjusted hazard ratios for time to maintenance dose in subcohort with adherence 
data. 
 
 
  
Factora 
(N = 143)b 
Unadjusted Adjusted (– Adherence) Adjusted (+ Adherence)e 
Hazard  
Ratioc 
P-valued 
Hazard  
Ratioc 
P-valued 
Hazard  
Ratioc 
P-valued 
≥ 80% adherencef 1.95  
(1.06, 3.59) 
0.032 — — 1.70  
(0.88, 3.27) 
0.11 
African American 0.88  
(0.54, 1.43) 
0.60 0.84  
(0.44, 1.61) 
0.61 0.90  
(0.46, 1.76) 
0.77 
Previous use of 
warfarin 
0.67  
(0.41, 1.11) 
0.12 0.58  
(0.32, 1.03) 
0.063 0.59  
(0.32, 1.07) 
0.084 
Current smoker 0.75  
(0.39, 1.44) 
0.39 0.68  
(0.31, 1.47) 
0.32 0.70  
(0.33, 1.52) 
0.37 
No. doctor’s visits 
in previous year: 
      
< 4 0.52  
(0.32, 0.85) 
0.026 0.47  
(0.27, 0.82) 
0.026 0.51  
(0.28, 0.91) 
0.053 
4 – 12 —  —  —  
> 12 0.67  
(0.35, 1.29) 
 0.68  
(0.29, 1.57) 
 0.61  
(0.27, 1.41) 
 
Fair/poor general 
health 
0.64  
(0.40, 1.01) 
0.055 0.63  
(0.36, 1.10) 
0.10 0.69  
(0.39, 1.22) 
0.20 
History of 
arrhythmia 
1.14  
(0.74, 1.78) 
0.55 1.01  
(0.57, 1.79) 
0.97 1.00  
(0.57, 1.76) 
>0.99 
VKORC1 variant 0.96  
(0.62, 1.47) 
0.84 1.06  
(0.57, 1.98) 
0.85 1.01  
(0.54, 1.88) 
0.97 
aAll non-genetic factors, excluding adherence, are based on self-report. Age was excluded from this 
analysis to prevent over-adjustment, because it is a known strong predictor of warfarin adherence while 
being very weakly associated with TTM. Illegal injectable drug use was excluded because there were 
too few self-reported users in the subcohort to produce stable estimates. 
bBoth unadjusted and adjusted results are from the same complete-case dataset to improve 
comparability; only individuals with adherence data were included in this analysis. 
cHazard ratios and confidence intervals are based on the mean and variance from 1,000 bootstrap 
replications. Hazard ratios less than 1 indicate longer time to maintenance dose; hazard ratios greater 
than 1 indicate shorter time to maintenance dose. 
dAll P-values are based on the Wald test using the mean and variance of estimates from 1,000 bootstrap 
replications. Categorical variables were tested jointly. 
eThe adjusted model also included visit number to ensure that visit frequency was not confounding the 
time-varying covariate. 
fAdherence was specified in a time-varying fashion, indicating whether the participant had correct 
adherence on ≥ 80% of the days over the last 3 visits, using medication event monitoring system 
(MEMS) data. 
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Table 2.10. Adjusted hazard ratios for time to maintenance dose using inverse probability of censoring 
weights. 
 
 
DISCUSSION 
In this study, we examined the social, clinical, and genetic factors associated with TTM, using the 
IN-RANGE prospective cohort of adults initiating warfarin therapy. We found that previous use 
of warfarin, current smoking status, having fewer than 4 doctor’s visits in the previous year, and 
worse general health status were all associated with longer TTM, while use of illegal injectable 
drugs was associated with shorter TTM. To our knowledge, this study is the first systematic 
examination of all of these factors for the clinically-relevant outcome of TTM in patients 
initiating warfarin. 
Baseline Factora 
(N = 358) 
Adjusted 
IPCW Hazard Ratiob P-valuec 
Age (years) 1.01 (1.00, 1.02) 0.16 
African American 1.00 (0.72, 1.37) 0.98 
Previous use of warfarin 0.66 (0.49, 0.91) 0.011 
Current smoker 0.65 (0.44, 0.98) 0.040 
Illegal injectable drug use 2.25 (1.20, 4.24) 0.012 
No. doctor’s visits in 
previous year: 
  
< 4 0.68 (0.51, 0.92) 0.038 
4–12 —  
> 12 0.94 (0.67, 1.34)  
Fair/poor general health 0.62 (0.46, 0.82) 0.001 
VKORC1 variant 1.32 (1.00, 1.74) 0.054 
aAll non-genetic factors are based on self-report. 
bHazard ratios less than 1 indicate longer time to maintenance dose; 
hazard ratios greater than 1 indicate shorter time to maintenance dose. 
Inverse probability of censoring weights were constructed from a Cox 
model with covariates including income, difficulty obtaining health 
care, previous warfarin use, warfarin indication, number of 
hospitalizations in previous year, number of doctor’s visits in previous 
year, statin use, history of pulmonary embolism, history of congestive 
heart failure, VKORC1, APOE ε2, INR value, visit number, warfarin 
adherence, and clinic site. 
cAll P-values are based on the Wald test, using robust standard errors to 
account for the non-independence of the weighted samples. Categorical 
variables were tested jointly. 
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Primary Analysis. Most of the literature on factors associated with TTM has focused on the 
effects of genetic variants, and our findings for genetic variants are largely consistent with these 
previous studies. None of the genetic variants studied were significantly associated with TTM. 
Like other prospective studies [Jorgensen et al., 2009; Limdi et al., 2008], we failed to observe an 
association between CYP2C9*2 or *3 and TTM in either African Americans or Caucasians. 
While evidence suggests that CYP2C9*5, *6, *8, and *11 may be more important than 
CYP2C9*2 and *3 for determining warfarin maintenance dose in African Americans due to their 
higher prevalence [Cavallari et al., 2010], significant associations between these variants and 
TTM have not been observed in previous studies [Limdi et al., 2008]. 
 
Similarly, VKORC1 was not significantly associated with TTM in either African Americans or 
Caucasians, which is consistent with the overall literature [Cavallari et al., 2011; Higashi et al., 
2002; Jorgensen et al., 2009; Limdi et al., 2008; Meckley et al., 2008]. Our hazard ratio in 
African Americans, however, was similar to that observed by Limdi et al. [Limdi et al., 2008], 
although none of these results were statistically significant. Our study was sufficiently powered to 
detect clinically meaningful hazard ratios, and even when adjusting for multiple variables we had 
more than 26 events per degree of freedom in our model, well more than the generally 
recommended 10 events per degree of freedom [Concato, Peduzzi, Holford, & Feinstein, 1995; 
Peduzzi, Concato, Feinstein, & Holford, 1995]. Thus, if there is indeed a real effect, it seems 
likely to be of small magnitude. Finally, our results did not confirm a previous finding of an 
association between APOE and TTM in African Americans [Cavallari et al., 2011]. However, this 
previous study excluded individuals who did not reach maintenance dose and had limited 
adjustment for confounders. Therefore, the previous finding could have been the result of 
selection bias, since many individuals who failed to reach maintenance dose could have had a 
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prolonged dose titration period, or bias from unmeasured confounding of clinical, social, and 
behavioral factors.  
 
By contrast, non-genetic factors—including behavioral factors (e.g. smoking status), health care 
utilization (e.g. number of doctor’s visits in the previous year), and health quality (e.g. self-
reported general health status)—appeared to be more important than genetic factors for 
determining TTM (Table 2.6). Worse general health status has been previously shown to be 
associated with worse warfarin adherence [Platt et al., 2010], and current smoking status has been 
associated with increased warfarin dose requirement [Gage et al., 2008; Nathisuwan et al., 2011] 
as well as decreased time in therapeutic range [Apostolakis et al., 2013], so it is unsurprising that 
these factors were found to be associated with longer TTM. Furthermore, fewer than 4 doctor’s 
visits in the previous year might be a marker for reduced health care access or health literacy, so 
it could conceivably be related to longer TTM through the effect of these factors on medication 
adherence and INR monitoring burden. Having fewer doctor’s visits in the previous year may 
also be associated with better general health status; however, the effects of being poorly 
integrated into the health care system on TTM likely overwhelm any benefits of better health. 
 
More surprising was the finding that previous use of warfarin was associated with longer, rather 
than shorter, TTM. Previous warfarin users did not differ from new warfarin users in terms of 
their warfarin indication or comorbidities (data not shown); however, they did appear to have 
their INRs checked less frequently, with 32% of previous warfarin users being seen at least once 
per week on average compared to 45% for new warfarin users, although this difference was not 
statistically significant (Table 2.11). One can hypothesize that physicians may have monitored 
patients with prior warfarin experience less frequently, thus leading to a longer TTM; however, 
this explanation likely does not fully explain the observed association, as previous warfarin use   
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Table 2.11. Association between significant factors and overall visit frequency. 
 
was still moderately associated with longer TTM in the sensitivity analysis using visit number, 
rather than days, as the unit of time.  
 
Similarly, the finding that patients who reported using illegal injectable drugs tended to have a 
shorter TTM was counterintuitive. While it is possible that physicians were intentionally 
monitoring these patients more closely, confirmatory evidence will be needed before concluding 
that the observed association was not primarily due to chance. Changes in post-initiation factors 
were also not associated with TTM, suggesting either that most of these changes typically do not 
occur early enough in the course of therapy to have a substantial impact on TTM or that they are 
Factora 
(N = 390) 
Median Number  
of Visits to  
Maintenance Doseb 
Overall Visit Frequencyc 
P-valued 
< 1 per week ≥ 1 per week 
Current smoker:     
No 7 (4, 12) 180 (55) 146 (45) 0.21 
Yes 8 (4, 21) 47 (73) 17 (27)  
Illegal injectable  
drug use: 
    
No 7 (4, 13) 218 (59) 153 (41) 0.076 
Yes 4 (3, 12) 8 (44) 10 (56)  
Previous use of 
warfarin: 
    
No 7 (4, 11) 161 (55) 130 (45) 0.12 
Yes 8 (4, 16) 65 (68) 31 (32)  
No. doctor’s visits  
in previous year: 
    
< 4 8 (5, 14) 62 (61) 39 (39) 0.70 
4–12 6 (4, 10) 102 (55) 85 (45)  
> 12 7 (3, 24) 61 (62) 37 (38)  
General health:     
Excellent/Very 
Good/Good 
6 (4, 11) 141 (55) 115 (45) 0.39 
Fair/poor 9 (4, 16) 81 (64) 45 (36) 0.21 
aAll factors from Table 2.6 that were found to be significantly associated with TTM were 
included here. 
bResults are reported as median (IQR). 
cResults are reported as N (%) for each level of visit frequency for each covariate. 
dP-values are based on the likelihood ratio test from a logistic regression model, adjusted for 
anticoagulation clinic site; categorical variables were tested jointly. 
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identified by physicians and appropriate dose adjustments are made during the dose titration 
period. However, changes in post-initiation factors could still be important determinants of 
anticoagulation control in patients on long-term warfarin therapy after maintenance dose has been 
achieved and monitoring is typically less frequent. Finally, it is also worth noting that most 
traditional clinical and demographic factors were not associated with TTM, including all clinical 
comorbidities examined and use of interacting medications at baseline. 
 
Secondary Analyses. Better adherence was not significantly associated with shorter TTM after 
adjustment for covariates. However, given that the point estimate for adherence was comparable 
to significant factors in the primary analysis, it seems plausible that there could be a real effect. 
Because of their shorter half-lives and inability to monitor, there is some concern that 
nonadherent patients on alternative oral anticoagulants might be expected to have worse 
outcomes than nonadherent warfarin patients [Avorn, 2011]. Future studies are needed to clarify 
the effect of adherence on TTM and the effects of adherence on outcomes with alternative oral 
anticoagulants. 
 
Limitations. There are several potential limitations of this study: 1) While one strength of our 
study is that we included all available follow-up time in our analyses, there is still the possibility 
of bias due to informative censoring. We attempted to assess the impact of informative censoring 
by performing a sensitivity analysis incorporating inverse probability of censoring weights. 
Because the results were not appreciably changed, we can be more confident that informative 
censoring is not substantially biasing our results. 2) Because INRs were checked only at visits to 
the anticoagulation clinic, there is the potential for interval censoring to bias our results. While 
the potential bias was small due to visits typically being only about a week or two apart, we 
attempted to determine the effect of interval censoring through a sensitivity analysis in which 
33 
 
visit number was the unit of time for the analysis. The fact that the results were not substantially 
changed makes us more confident in the robustness of our results. 3) We were limited to the 
variables available in this cohort; thus, there may have been other important predictors of TTM 
that we could not assess or residual confounding of the variables we did examine. For this reason, 
future studies of TTM will likely need better measurement of social, behavioral, and health care 
access factors, as well as medication adherence. 4) This study used the same dataset for variable 
selection and effect estimation, potentially leading to problems with overfitting. To address this 
issue, we bootstrapped all point estimates and confidence intervals in both primary and secondary 
analyses. Bootstrapped results were not substantially different from standard estimates; however, 
these results will still need independent validation. 5) Finally, these data are from specialty 
anticoagulation clinics, potentially reducing their generalizability to warfarin patients in other 
clinical settings. 
 
Conclusions. In conclusion, TTM was associated with baseline behavioral factors, health care 
utilization, and health quality in patients initiating warfarin, while traditional clinical 
comorbidities and genetic factors appeared less important. The observed associations could 
plausibly be related to differences in warfarin adherence and visit frequency that occur after 
warfarin initiation, through their effects on anticoagulation control. Future studies will be needed 
to address whether warfarin patients with prolonged TTM will have better outcomes on 
alternative oral anticoagulants.  
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CHAPTER 3. CAN WE PREDICT PROLONGED DOSE TITRATION IN 
PATIENTS STARTING WARFARIN? 
 
Brian S Finkelman, Benjamin French, Luanne Bershaw, Colleen M Brensinger,  
and Stephen E Kimmel 
 
 
ABSTRACT 
Background. Patients initiating warfarin therapy generally experience a dose-titration period of 
weeks to months, during which time they are at particularly high risk of both thromboembolic and 
bleeding events. Accurate prediction of which patients are at higher risk of prolonged dose 
titration could help clinicians determine which patients might be better treated by alternative 
anticoagulation therapies that, while more costly, do not require dose titration. 
 
Methods. Prolonged dose titration was defined as having a time to maintenance dose of greater 
than 12 weeks. The prediction model was derived in a prospective cohort of patients initiating 
warfarin (N = 390), using a Cox proportional hazards model to account for censoring, and then 
validated in an external cohort (N = 663). Predictor variables were selected using a modified best 
subsets algorithm, incorporating cross-validation to reduce overfitting.  
 
Results. Five predictor variables were selected for inclusion in the prediction model: warfarin 
indication, insurance status, number of doctor’s visits in the previous year, current smoking 
status, and history of congestive heart failure. The AUC of this model in the derivation cohort, as 
estimated using leave-one-out cross-validation, was 0.66 (95% CI 0.60, 0.74), while in the 
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external validation cohort, the AUC was only 0.59 (95% CI 0.54, 0.64). Including genetic factors 
in the model did not improve the AUC (0.59; 95% CI 0.54, 0.64). Examination of relative utility 
indicated that use of the prediction model was unlikely to provide a clinically meaningful benefit 
for patients. 
 
Conclusion. Our results suggest that prolonged dose titration cannot be accurately predicted in 
warfarin patients, at least using traditional clinical, social, and genetic predictors. Our results also 
highlight the general need for external validation when constructing risk prediction models. 
 
BACKGROUND 
Because of the substantial population-level variability in warfarin dose requirement, patients 
starting warfarin therapy will often experience a lengthy dose-titration period of weeks to months. 
During this period, they are at particularly high risk of both bleeding and thromboembolic 
complications from improper anticoagulation levels [Fihn et al., 1993; Hylek et al., 1996]. 
Patients with a prolonged dose-titration period also face increased burden from more frequent 
international normalized ratio (INR) monitoring, which can lead to a reduced quality of life and 
higher rates of discontinuation of a highly efficacious therapy [Arnsten et al., 1997; Dantas et al., 
2004; Fang et al., 2010]. Given the availability of less burdensome but more expensive alternative 
oral anticoagulants [Avorn, 2011]—including dabigatran, rivaroxaban, and apixaban—accurate 
prediction of which patients are likely to experience a prolonged dose-titration period on warfarin 
could potentially help clinicians decide when to use warfarin versus one of the alternative agents. 
Thus, we sought to develop and externally validate a model to predict prolonged dose titration in 
patients initiating warfarin therapy. 
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METHODS 
Overview. We derived a prediction model for whether a patient initiating warfarin achieved 
maintenance dose within the first 12 weeks of attempted therapy, using a Cox proportional 
hazards model. We then validated this model in an external prospective cohort of patients 
initiating warfarin. All analyses were performed in R 3.1.0 [R Development Core Team, 2014]. 
 
Derivation cohort. We derived the prediction model using the IN-RANGE cohort, a large 
prospective cohort of warfarin initiation that has been used to study the clinical and genetic 
predictors of warfarin maintenance dose and adherence [Kealey et al., 2007; Kimmel et al., 2007, 
2008; Parker et al., 2007; Platt et al., 2008, 2010; Schelleman et al., 2010, 2007; Schelleman, 
Chen, et al., 2008]. Participants were recruited from specialty anticoagulation clinics at the 
Hospital of the University of Pennsylvania (HUP), the Philadelphia Veterans Affairs Medical 
Center (PVAMC), and Hershey Medical Center. Institutional review board approval was obtained 
at all three sites, and all study participants provided written informed consent. Exclusion criteria 
were kept to a minimum to ensure patient generalizability. Specific exclusion criteria included 
being under 21 years old, being unwilling or unable to provide consent, having an abnormal INR 
prior to starting warfarin or heparin therapy, or the presence of antiphospholipid antibodies. 
Participants were enrolled between April 2002 and February 2006. All participants in the original 
IN-RANGE cohort (N = 390) were included as part of the derivation cohort for the current study. 
 
Validation cohort. Once the prediction model was developed, it was then validated in an external 
cohort. The cohort used for validation was the IN-RANGE2 cohort, which was designed as a 
follow-up cohort to the original IN-RANGE cohort, with similar data collection methods. 
Participants were recruited from specialty anticoagulation clinics at HUP, PVAMC, and Johns 
Hopkins University (JHU). Institutional review board approval was obtained at all three sites, and 
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all study participants provided written informed consent. Exclusion criteria were purposefully 
kept similar to the original IN-RANGE cohort, with the only difference being that individuals 
who were neither Caucasian nor African American (about 3% of the original cohort) were 
excluded from the IN-RANGE2 study and that the presence of antiphospholipid antibodies was 
dropped as an exclusion criterion for the IN-RANGE2 study. Participants were enrolled between 
October 2009 and August 2013. All participants with data available as of August 2014 (N = 663) 
were included in the validation cohort for the current study. 
 
Primary outcome. The primary outcome was a prolonged dose-titration phase, defined as whether 
an individual achieved maintenance dose within 12 weeks of attempted warfarin therapy. The 12 
week cut-off was selected as a clinically meaningful cut-off, as the first 3 months of warfarin 
therapy have been shown to be especially high risk for patients [Fihn et al., 1993], and some 
warfarin indications, such as venous thromboembolism with transient risk factors, often only 
require a 3 month course of therapy [Agnelli & Becattini, 2008]. Additionally, we used a 
dichotomous rather than continuous outcome, such as time to maintenance dose, to make it easier 
for clinicians to incorporate model predictions into their decision-making process. Achievement 
of maintenance dose was defined as having two consecutive INRs within the therapeutic range, at 
the same warfarin dose, at least one week apart. Use of this definition allowed for the outcome to 
be defined the same across both the derivation and validation cohorts. Additionally, the time of 
maintenance dose achievement was taken as the number of days from warfarin initiation to the 
first maintenance dose-defining visit in days. Reaching maintenance dose within 4 and 8 weeks 
were also considered as outcomes in secondary analyses. 
 
Candidate predictors. A total of 28 candidate baseline social and clinical factors were considered 
for inclusion in the primary prediction model, shown in Table 3.1. Most of these candidate   
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Table 3.1. Candidate baseline social and clinical predictors and their specifications. 
Candidate Predictor Specification 
Social  
Self-reported race Binary (0 = not African American; 1 = African American) 
Gender Binary (0 = male; 1 = female) 
Marital status Categorical (1 = married (ref); 2 = separated/divorced;  
3 = widowed; 4 = never married) 
Employment status Categorical (1 = working; 2 = unemployed/disabled;  
3 = retired (ref)) 
Education statusa Binary (0 = more than high school; 1 = high school or less) 
Insurance status Categorical (1 = private (ref); 2 = any VA/Medicare only;  
3 = Medicaid/no insurance) 
Number of alcoholic  
drinks per weeka 
Binary (0 = 0 drinks; 1 = 1 or more drinks) 
Current smoking status Binary (0 = not current smoker; 1 = current smoker) 
Self-reported general  
health status 
Categorical (1 = excellent/very good (ref); 2 = good;  
3 = fair/poor) 
No. hospitalizations  
in past 12 months 
Categorical (1 = 0  visits (ref); 2 = 1–2 visits; 3 = 3 or more 
visits) 
No. doctor’s visits  
in past 12 months 
Categorical (1 = 0–3  visits; 2 = 4–12 visits (ref); 3  = 13 or 
more visits) 
Had difficulty receiving 
 health care in the past  
12 months 
Binary (0 = no; 1 = yes) 
  
Clinical  
Age (years) at baseline visit Continuous (linear) 
Body Mass Indexa Continuous (linear) 
Previous use of warfarina Binary (0 =  no; 1 = yes) 
Warfarin indication Categorical (1 = atrial fibrillation/atrial flutter (ref); 2 = post 
deep vein thrombosis/pulmonary embolism; 3 = other)  
Number of interacting  
medications being used  
at baselinea 
Binary (0 = 0–1 medications; 1 = 2 or more medications) 
Amiodarone use at baselinea Binary (0 =  no; 1 = yes) 
Statin use at baseline Binary (0 =  no; 1 = yes) 
CHADS2 score Categorical (1 = 0 (ref); 2 = 1; 3 = 2 or higher) 
History of peptic ulcer  
disease or gastritis 
Binary (0 =  no; 1 = yes) 
History of stroke Binary (0 =  no; 1 = yes) 
History of cancer Binary (0 =  no; 1 = yes) 
History of hypertension Binary (0 =  no; 1 = yes) 
History of diabetesa Binary (0 =  no; 1 = yes) 
History of arrhythmia Binary (0 =  no; 1 = yes) 
History of congestive  
heart failure 
Binary (0 =  no; 1 = yes) 
History of myocardial 
infarctiona 
Binary (0 =  no; 1 = yes) 
aThese variables were excluded from the model via a univariable screen, described in the 
Methods section. 
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predictors have been previously associated with other warfarin-related outcomes, such as warfarin 
maintenance dose requirement [Gage et al., 2008; Klein et al., 2009], poor warfarin adherence 
[Arnsten et al., 1997; Platt et al., 2008, 2010], discontinuation of warfarin [Bushnell et al., 2011; 
Fang et al., 2010; Song, Sander, Varker, & Amin, 2012], percent time in therapeutic range 
[Hylek, Heiman, Skates, Sheehan, & Singer, 1998; Kimmel et al., 2007; Wieloch et al., 2011], 
and risk of bleeding events [Beyth et al., 1998; Gage et al., 2006; Lip et al., 2011; Shireman et al., 
2006]. Additionally, after constructing a model from baseline social and clinical factors, we were 
interested in whether inclusion of genetic factors could improve model prediction. For this 
analysis, we added genetic variants in CYP2C9 (rs1799853 and rs1057910) and VKORC1 
(rs9923231), specified in a binary fashion as having at least one variant in the given gene, to the 
model. These variants were chosen because they have most consistently demonstrated a large 
association with warfarin maintenance dose in the literature, and are used in the major 
pharmacogenetic dosing algorithms [Gage et al., 2008; Kimmel et al., 2013; Klein et al., 2009]. 
 
Choice of statistical model. Because approximately 11% of the derivation cohort was censored 
prior to 12 weeks of attempted warfarin therapy, we needed to use a statistical model that could 
accommodate censoring. As a result, we used a Cox proportional hazards model with time from 
initiation of warfarin to the achievement of maintenance dose or censoring in days as the 
outcome. The probability of prolonged dose titration was, thus, the conditional probability of 
survival predicted from this model at the time-point of interest, 12 weeks of attempted warfarin 
therapy. Because we were not interested in modeling follow-up time after this cut-off point, all 
individuals who had not reached maintenance dose by 12 weeks were artificially censored at this 
time.  
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Univariable screen. To reduce overall computing time for our analyses to manageable levels, we 
chose to perform a univariable screen to reduce the number of candidate predictors from the 
initial 28 to 20, which was determined a priori to be an appropriate number of candidate 
variables, given computational constraints. For each candidate predictor, we constructed a 
univariable Cox proportional hazards model of the time from initiation of warfarin to the 
achievement of maintenance dose or censoring. We then estimated the time-dependent area under 
the ROC curve (AUC) at 12 weeks of follow-up using 10-fold cross-validation for each model. 
The 20 variables with the best time-dependent AUCs in the univariable screen were selected for 
inclusion in the modified best subsets variable selection algorithm, described below. 
 
Time-dependent AUC. The time-dependent AUC—developed by Heagerty, et al. [Heagerty, 
Lumley, & Pepe, 2000]—differs from the standard AUC because it accommodates censoring, and 
it differs from the commonly used C-index because it assesses model discrimination at a single 
point in time, rather than over the total duration of follow-up. The time-dependent AUC can thus 
be interpreted as the probability that a randomly selected individual who has experienced the 
failure event by time t will have a higher predicted probability of failure at time t than a randomly 
selected individual who has not experienced the failure event by time t. This statistic is estimated 
by integrating the time-dependent sensitivity and specificity across all possible cut-off values for 
the linear predictor derived from the model. Because cross-validation was used during the model 
development process, the linear predictor was calculated in the data subset that was withheld 
during estimation of the Cox model, repeated for all data subsets (e.g. 10 times for 10-fold cross-
validation). When the model was assessed in the external validation cohort, the linear predictors 
in that cohort were used without cross-validation. 
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Because individuals may be censored prior to time t, the values for time-dependent sensitivity and 
specificity need to be estimated from the data. As recommended by Heagerty, et al., we used a 
nearest neighbor estimator—which is essentially a weighted Kaplan-Meier estimator based on a 
nearest neighbor kernel function, developed by Akritas [Akritas, 1994]—which allows for 
monotonicity of sensitivity and specificity and for the censoring process to depend on the 
predictive marker of interest. This estimator is dependent on a smoothing parameter,  , where 2  
represents the percentage of observations that are included in an individual observation’s 
neighborhood; in our case, we chose the default value of   = 0.025. The “survivalROC” package 
in R was used to facilitate these calculations [Heagerty & Saha-Chaudhuri, 2013]. 
 
Variable selection algorithm. Variable selection was conducted using a modified best subsets 
algorithm [Miller, 2002]. This algorithm was designed to optimize model discrimination, or how 
well a model distinguishes between those who did and did not experience the outcome (in this 
case, those who had a prolonged vs non-prolonged dose-titration phase, respectively). We 
calculated the time-dependent AUC at 12 weeks using 10-fold cross-validation for all possible 
combinations of the candidate predictors up to 10 predictor variables in length (616,665 
combinations) to reduce our chances of selecting a combination based on overfitting. Because we 
felt that leave-one-out cross-validation (LOOCV)—in which one person at a time is removed 
from the dataset to build the model and then used for model testing, for all individuals in the 
dataset—was a better estimate of external validation than 10-fold cross-validation [Hastie, 
Tibshirani, & Friedman, 2009], we opted to estimate the time-dependent AUC using LOOCV in 
the 1,000 best models based on 10-fold cross-validation for each subset size (8,210 
combinations). The combination of predictors that led to the highest time-dependent AUC using 
LOOCV was then selected as our final prediction model.  
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In short, our algorithm was designed to select the combination of candidate variables with the 
best estimated LOOCV time-dependent AUC. Furthermore, this strategy had the advantage of 
choosing the best subset based on LOOCV, without the nearly 40-fold increase in computing time 
that would be required by calculating the time-dependent AUC using LOOCV in all possible 
combinations of predictors. A sensitivity analysis showed that this algorithm selected the exact 
same best combination of predictor variables as using LOOCV on all possible combinations up to 
6 predictor variables in length. Once selected, prediction model variables were then inspected 
graphically to ensure proper functional form, and all coefficients were examined to ensure that 
the direction of effect reported by the model was consistent with the available literature. 
 
Linear shrinkage factor. Because regression coefficients are often overestimated in small 
samples, prediction models will often show better calibration for out-of-sample predictions when 
coefficients are shrunk toward zero [Van Houwelingen & Le Cessie, 1990]. Thus, we sought to 
apply a linear shrinkage factor—which has been shown to perform well in small samples for 
improving model calibration, without sacrificing model discrimination [Steyerberg, Eijkemans, 
Harrell, & Habbema, 2000]—to our final prediction model. To estimate the shrinkage factor, we 
fit the model in a bootstrap sample of the derivation cohort. We then calculated the linear 
predictors of the individuals in the derivation cohort using the model coefficients from the 
bootstrap sample. The slope of the actual observed outcomes regressed on these bootstrapped 
linear predictors could then be used as an estimate of the shrinkage factor. To form a stable 
estimate of the shrinkage factor, we calculated the mean slope over 1,000 bootstrap replications. 
All of the original model coefficients were then multiplied by this shrinkage factor to produce the 
final shrunk coefficients, which were used for generating predictions in the external validation 
cohort. Because all of the coefficients are being multiplied by the same factor, the rank order of 
individual predictions is preserved and model discrimination is not affected by shrinkage. 
43 
 
In order to ensure that shrinkage was toward the overall mean and not toward the overall 
reference category, continuous variables needed to be centered at the mean and categorical 
variables had to be coded using simple contrasts. In this contrast method, reference groups were 
coded as      , while non-reference categories were coded as (   )  , where   is the number 
of categories. In this contrast method, the reference category of 0 is equivalent to the overall 
mean of the sample in which the model is being fit. Note that the difference between the reference 
and non-reference categories is still 1; thus, the interpretation of coefficients in this contrast 
method is identical to the more common dummy coding for categorical variables (i.e. 0 for 
reference and 1 for non-reference categories). 
 
Model assessment and validation. The final prediction model was then assessed in a separate 
validation cohort, described above. Predictions from the model were used to estimate the time-
dependent AUC as the primary measure of model discrimination in the validation dataset. 
Additionally, genetic predictors were added to the model to see if there was a significant 
difference in the AUC between the two models. The integrated discrimination improvement (IDI) 
between the two models was also estimated [Liu, Kapadia, & Etzel, 2010]. We also assessed the 
calibration of the prediction model using calibration plots. Finally, we examined the clinical 
utility of the prediction model using decision curves and plots of the relative utility of the model 
versus the risk threshold [Baker, Cook, & Vickers, 2009; Baker, 2009; Vickers, Cronin, Elkin, & 
Gonen, 2008; Vickers & Elkin, 2006]. Confidence intervals for all estimates were generated using 
the 2.5th and 97.5th percentiles of estimates in 1,000 bootstrap replications. 
 
The methods for determining clinical utility rely on the concept of the risk threshold, which is the 
probability of the outcome at which the clinician is indifferent about which treatment strategy to 
use; in other words, it is the probability at which the costs of false positive and false negative 
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mistakes are equal [Pauker & Kassirer, 1975]. Furthermore, the consequences of basing a clinical 
decision on the predicted probability from a risk prediction model can be estimated as a function 
of the risk threshold. While the exact threshold will vary depending on the value that physicians 
and patients place on certain outcomes, the metric can be used to determine the clinical usefulness 
of a given model under a range of possible thresholds. For our prediction model, given broadly 
similar safety and efficacy profiles for warfarin and the alternative anticoagulants (with the 
possible exception of apixaban) [O’Dell, Igawa, & Hsin, 2012; Rollins, Silva, Donovan, & 
Kanaan, 2014], the risk threshold for a given patient would likely depend primarily on his or her 
relative costs of INR monitoring on warfarin versus the out-of-pocket financial costs of the 
alternative anticoagulant agents. In this scheme, patients that are more burdened by financial 
costs would have a risk threshold above 0.5, while those that are more burdened by INR 
monitoring would have a risk threshold below 0.5. 
 
Decision curves plot the net benefit of various treatment strategies versus the risk threshold, 
where the net benefit is equal to the true positive rate minus the false positive rate, weighted as a 
function of the risk threshold [Vickers & Elkin, 2006]. In this case, the net benefit is calculated 
relative to the strategy of using standard warfarin therapy in all patients. The curve shows the 
values of the risk threshold where using the prediction model would be expected to provide a net 
benefit above the strategies of using the same treatment in every patient. Relative utility is a 
related measure of the usefulness of a prediction model that is essentially a rescaling of the net 
benefit, and it can be interpreted as the net benefit of the prediction model, compared to using the 
same treatment strategy in all patients, as a fraction of the net benefit of perfect prediction [Baker 
et al., 2009]. A relative utility of 1 indicates that the model performs as well as perfect prediction, 
while negative values indicate that the model is worse than using the same strategy in everyone. 
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RESULTS 
The characteristics of the derivation and validation cohorts are shown in Table 3.2. The overall 
prevalence of prolonged dose-titration was 30% in the derivation cohort and 38% in the 
validation cohort. The variable selection algorithm found that the best LOOCV time-dependent 
AUC was in a model with the following five variables: warfarin indication, insurance status, 
number of doctor’s visits in the previous year, current smoking status, and history of heart failure. 
The LOOCV time-dependent AUC in this model was estimated as 0.66 (95% CI 0.60, 0.74). A 
comparison of this model to the other top performing models with different numbers of predictor 
variables, as measured with cross-validation, suggested that using cross-validation successfully 
avoided complex models that were more accurate merely because of having extra degrees of 
freedom (Figure 3.1). The shrinkage factor based on 1,000 bootstrap replications was estimated to 
be about 0.82, indicating a moderate degree of overfitting in the original model. Coefficients from 
the final prediction model, after applying the linear shrinkage factor, are shown in Table 3.3. 
 
When tested in the validation cohort, the AUC of the prediction model at 12 weeks was 0.59 
(95% CI 0.54, 0.64). The ROC curve for this model is shown in Figure 3.2. The AUC of the 
model at 8 weeks was 0.57 (95% CI 0.53, 0.62) and at 4 weeks was 0.57 (95% CI 0.52, 0.62). 
The calibration of the main model was examined by comparing predicted probabilities to 
observed frequencies across risk deciles (Figure 3.3); the Hosmer-Lemeshow test for goodness of 
fit did not show significantly poor model calibration (P = 0.73). Addition of genetic factors did 
not significantly change the AUC at 12 weeks (P > 0.99), with the point estimate remaining 
unchanged at 0.59 (95% CI 0.54, 0.64). A comparison of the ROC curves for the models with and 
without genetic factors is shown in Figure 3.4. The calibration of the genetic model, however, 
seemed worse than the main model, though the level of miscalibration was not significantly 
worse than what would be expected due to chance, using the Hosmer- Lemeshow test (P = 0.06).   
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Table 3.2. Characteristics of the derivation and validation cohorts. 
Variable 
Derivation cohort 
(N = 390)a 
Validation cohort 
(N = 663)a 
P-valueb 
Age    
< 45 65 (17) 135 (20) < 0.001 
45 – 55 74 (19) 131 (20)  
55 – 65 103 (26) 219 (33)  
65 – 75 83 (21) 116 (18)  
75+ 65 (17) 60 (9)  
Female gender 119 (31) 250 (38) 0.02 
African American race 174 (45) 466 (71) < 0.001 
Body Mass Index    
< 25 122 (32) 186 (28) 0.11 
25 – 30 125 (32) 189 (29)  
> 30 140 (36) 280 (43)  
History of hypertension 192 (49) 461 (70) < 0.001 
History of diabetes 107 (27) 190 (29) 0.71 
History of peptic ulcer  
disease 
36 (9) 98 (15) 0.01 
History of heart failure 78 (20) 141 (21) 0.65 
Warfarin indication    
AFib/AFlutter 188 (48) 214 (32) < 0.001 
DVT/PE 116 (30) 343 (52)  
Other 86 (22) 105 (16)  
Previously used warfarin 96 (25) 209 (32) 0.02 
Smoking status    
Never 141 (36) 275 (42) < 0.001 
Past 185 (47) 235 (36)  
Current 64 (16) 148 (22)  
Insurance status    
Private 215 (56) 276 (42) < 0.001 
VA/Medicare/Other 124 (32) 272 (41)  
Medicaid/None 45 (12) 110 (17)  
Employment status:    
Working 128 (33) 167 (25) < 0.001 
Unemployed 34 (9) 49 (7)  
Retired 143 (37) 192 (29)  
Disabled 81 (21) 251 (38)  
Annual income:    
< $15,000 109 (33) 228 (41) < 0.001 
$15,000 - $20,000 99 (30) 45 (8)  
> $20,000 122 (37) 282 (51)  
Site:    
HUP 184 (47) 263 (40) < 0.001 
PVAMC 137 (35) 198 (30)  
Hershey 69 (18) —  
JHU — 202 (30)  
aAll values are reported as N (%). 
bP-values are based on the chi-square test. 
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Figure 3.1. Comparison of best prediction models by number of predictor variables in the model. 
Prediction models compared by the time-dependent AUC at 12 weeks, as estimated by leave-one-out cross-
validation (LOOCV). 
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Table 3.3. Final prediction model coefficients. 
Predictor variable Shrunk coefficienta,b 
Warfarin indication 
AFib/Aflutter — 
DVT/PE -0.47 
Other -0.33 
Insurance status 
Private insurance — 
VA/Medicare -0.14 
Medicaid/None -0.42 
Number MD visits in previous year 
<4 -0.29 
4-12 — 
>12 -0.23 
Current smoker -0.17 
History of heart failure -0.21 
aCoefficients were multiplied by a linear shrinkage factor, 
equal to about 0.82, based on 1,000 bootstrap replications. 
bNegative coefficients indicate a higher probability of 
prolonged dose titration. 
Figure 3.2. ROC curve for the prediction model as tested in the validation dataset. 
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Figure 3.4. Comparison of ROC curves for the prediction models with and without the addition of genetic 
factors. 
Figure 3.3. Predicted probability vs observed frequency of prolonged dose titration by risk decile. 
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The integrated discrimination improvement from adding genetic factors to the model was 
estimated as 0.01 (0.00, 0.02), which is equivalent to a 7% increase in model discrimination over 
the model without genetic factors. 
 
To examine the clinical utility of the prediction model, the sensitivity, specificity, and positive 
and negative predictive values for various risk thresholds were calculated (Table 3.4). Similarly, 
Figure 3.5 shows the relationship between the positive and negative predictive values and the 
proportion that are classified as positive across the full range of risk thresholds. Predicted 
probabilities of prolonged dose titration in the validation cohort ranged from about 16% to 63%; 
thus, predictive values only varied over this range. The relative utility of the model—which can 
be understood as the net benefit of the current model, compared to not using a prediction model, 
as a fraction of the net benefit of perfect prediction—across the full range of risk thresholds is 
shown in Figure 3.6. The maximum relative utility observed was 9.4%, and the relative utility 
was negative for the risk threshold range of 48% to 62%. Comparisons of relative utility and 
decision curves for the models with and without genetic factors are shown in Figures 3.7 and 3.8, 
respectively. 
 
We also examined site-specific differences in model performance in post-hoc analyses. 
Differences in the characteristics of the derivation and validation cohorts at HUP and PVAMC 
are shown in Table 3.5. The time-dependent AUC at 12 weeks was 0.60 (95% CI 0.51, 0.67) at 
HUP, 0.55 (95% CI 0.45, 0.63) at PVAMC, and 0.61 (95% CI 0.53, 0.69) at JHU. Finally, the 
observed frequency of prolonged dose titration was 32%, 34%, and 48% at HUP, PVAMC, and 
JHU, respectively; predicted probabilities of the outcome at the respective sites, however, were 
37%, 39%, and 38%. 
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Table 3.4. Model characteristics at various risk thresholds. 
Risk thresholda CFP/CFN
b Sensitivity Specificity 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Proportion 
Predicted 
Positive 
10% 0.11 1.00 0.00 0.37 — 1.00 
20% 0.25 0.99 0.03 0.38 0.87 0.98 
30% 0.43 0.83 0.28 0.41 0.74 0.76 
40% 0.67 0.52 0.58 0.43 0.67 0.46 
50% 1 0.19 0.86 0.44 0.64 0.16 
60% 1.5 0.03 0.99 0.57 0.63 0.02 
70% 2.33 0.00 1.00 — 0.63 0.00 
aThe risk threshold refers to the cut-off probability, where one classifies individuals as positive when 
predicted to be above the cut-off or negative when predicted to be below the cut-off. In this case, 
being “positive” refers to having a high probability of prolonged dose titration on warfarin, 
potentially leading a physician to choose an alternative therapy. 
bCFP/CFN refers to the ratio of the costs of false positive and false negative mistakes that are implied 
by the risk threshold, according to decision theory. 
Figure 3.5. Positive predictive value, negative predictive value, and proportion of patients classified as 
positive across the range of values for the risk threshold. Individuals with a predicted probability of 
prolonged dose titration are classified as positive. The absence of a curve in a given region indicates that 
the measure is undefined in that region; for instance, positive predictive value is undefined when no 
patients are classified as positive. 
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Figure 3.7. Comparison of relative utility curves in prediction models with and without genetic factors. 
Figure 3.6. Relative utility of the prediction model across the full range of risk thresholds. 
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Figure 3.8. Decision curve of prediction models with and without genetic factors. In this case, the decision 
curve plots the net benefit of the prediction model compared to the strategy of using standard warfarin 
treatment in everyone, across the full range of values for the risk threshold. The strategy of using standard 
warfarin treatment in everyone is shown with the solid black line, while the strategy of using an 
alternative therapy in everyone is shown with the dashed black line. The net benefit of the strategies of 
using standard warfarin therapy in everyone and using an alternative therapy in everyone intersects when 
the risk threshold is equal to the prevalence of the outcome in the overall population. Note that the curve 
for the all on alternative therapy strategy continues downward beyond the edge of the figure. 
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Table 3.5. Characteristics of the derivation and validation cohorts by site. 
 
  
Variable 
HUPa PVAMCa 
Derivationb 
(N = 184) 
Validationb 
(N = 263) 
Derivationb  
(N = 137) 
Validationb  
(N = 198) 
Age     
< 45 51 (28) 75 (29) 12 (9) 7 (4) 
45 – 55 39 (21) 61 (23) 23 (17) 28 (14) 
55 – 65 35 (19) 62 (24) 57 (42) 96 (48) 
65 – 75 35 (19) 41 (16) 28 (20) 45 (23) 
75+ 24 (13) 23 (9) 17 (12) 22 (11) 
Female gender 89 (48) 136 (52) 5 (4) 9 (5) 
African American race 103 (56) 188 (71) 70 (51) 147 (74) 
Body Mass Index     
< 25 63 (34) 66 (25) 41 (30) 62 (31) 
25 – 30 62 (34) 77 (30) 36 (26) 57 (29) 
> 30 59 (32) 117 (45) 59 (43) 79 (40) 
History of hypertension 87 (47) 170 (65) 66 (48) 151 (76) 
History of diabetes 40 (22) 68 (26) 50 (36) 71 (36) 
History of peptic ulcer disease 16 (9) 26 (10) 17 (12) 9 (5) 
History of heart failure 31 (17) 58 (22) 34 (25) 40 (20) 
Warfarin indication     
AFib/AFlutter 68 (37) 81 (31) 70 (51) 87 (44) 
DVT/PE 73 (40) 131 (50) 40 (29) 86 (44) 
Other 43 (23) 51 (19) 27 (20) 24 (12) 
Previously used warfarin 47 (26) 75 (29) 40 (29) 72 (36) 
Smoking status     
Never 90 (49) 130 (50) 19 (14) 37 (19) 
Past 73 (40) 87 (34) 79 (58) 92 (46) 
Current 21 (11) 42 (16) 39 (28) 69 (35) 
Insurance status     
Private 151 (84) 162 (63) 6 (4) 10 (5) 
VA/Medicare/Other 7 (4) 43 (17) 107 (79) 154 (78) 
Medicaid/None 21 (12) 54 (21) 23 (17) 34 (17) 
Employment status:     
Working 79 (43) 78 (30) 32 (24) 18 (9) 
Unemployed 17 (9) 22 (8) 17 (13) 12 (6) 
Retired 49 (27) 62 (24) 49 (36) 91 (46) 
Disabled 39 (21) 99 (38) 37 (27) 77 (39) 
Annual income:     
< $15,000 48 (29) 90 (37) 41 (38) 95 (49) 
$15,000 - $20,000 45 (27) 18 (7) 48 (45) 18 (9) 
> $20,000 72 (44) 137 (56) 18 (17) 79 (41) 
aSites were limited to those that were present in both derivation and validation cohorts. 
bAll values are reported as N (%). 
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DISCUSSION 
Overview. In this study, we sought to develop a model to predict whether a patient starting 
warfarin would have a prolonged dose-titration phase, and then test the model in an external 
validation cohort. Given the availability of less burdensome but more expensive alternative oral 
anticoagulant agents, being able to predict prolonged dose titration could help patients and 
clinicians decide whether to use warfarin or one of the alternative agents. However, the prediction 
model we developed failed to validate in an external cohort, with an AUC of 0.59 (95% CI 0.54, 
0.64). Thus, our results suggest that it will be difficult for clinicians to predict prolonged dose 
titration in patients starting warfarin, at least using traditional social, clinical, and genetic 
predictors. 
 
Model development. The final model contained five variables: warfarin indication, insurance 
status, number of doctor’s visits in the previous year, current smoking status, and history of heart 
failure. This model performed moderately well in the derivation cohort, with a time-dependent 
AUC at 12 weeks, as measured by LOOCV, of 0.66 (95% CI 0.60, 0.74). Furthermore, only a 
moderate amount of shrinkage was needed to improve model calibration, with a linear shrinkage 
factor of 0.82. Finally, the association between the selected predictor variables and the outcome 
seemed to be quite stable, as these predictors were seen in the best models across the full range of 
subset sizes (Figure 3.1). 
 
Model validation. The model performed much worse when tested in the external validation 
cohort, however. The time-dependent AUC at 12 weeks was only 0.59 (95% CI 0.54, 0.64) when 
validated externally. Model performance did not improve for the secondary outcomes of reaching 
maintenance doses within 4 and 8 weeks, indicating that the model’s limited ability to 
discriminate was not unique to a specific time point cut-off. Although the variable selection 
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algorithm was designed to optimize model discrimination, the model appeared to be reasonably 
well calibrated in the overall validation cohort, with a non-significant Hosmer-Lemeshow 
calibration test (P = 0.73). This result suggests that our use of a linear shrinkage factor was 
largely successful in improving model calibration. However, we believe that model 
discrimination is the best way to determine the clinical utility of this prediction model, because it 
would allow clinicians to distinguish between patients at higher risk for prolonged dose titration 
on warfarin from those at lower risk. 
 
The addition of genetic variants did not improve the performance of the model, with no 
improvement in the time-dependent AUC observed (P > 0.99). Similarly, the IDI was also poor at 
0.01 (95% CI 0.00, 0.02), although it was technically a statistically significant improvement in 
discrimination. The IDI as a test statistic is known to have problems with type I error, especially 
as it approaches zero [Kerr, McClelland, Brown, & Lumley, 2011; Pepe, Feng, & Gu, 2008], so 
this finding of statistical significance should be viewed with skepticism in the context of the rest 
of our results. Overall, the lack of improvement in prediction from adding genetic factors is 
consistent with recent clinical trial evidence showing that inclusion of genetic factors in dose 
prediction models did not lead to significant improvement in clinical outcomes, such as percent 
time in therapeutic range or time to maintenance dose, over purely clinical dose prediction 
algorithms [Kimmel et al., 2013]. 
 
Differences between derivation and validation cohorts. One reason for the failure of the model to 
validate is likely the substantial differences between the derivation and validation cohorts, as 
shown in Table 3.2. Compared with the derivation cohort, the validation cohort was younger, 
more African American, more obese, more under-insured, and more disabled, among other 
differences. These differences are likely reflected in the fact that the prevalence of prolonged 
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dose titration was higher in the validation cohort at 38%, compared to 30% in the derivation 
cohort. Part of these differences might reflect discrepancies in populations at different sites; for 
example, the anticoagulation clinic at Johns Hopkins draws from a much more urban African 
American population than the clinic at Hershey Medical Center. However, there are also 
substantial differences between the derivation and validation cohorts at the sites that were the 
same for both cohorts, including the proportion of individuals who are African American, the 
prevalence of hypertension, the prevalence of different warfarin indications, and the proportion of 
individuals on disability (Table 3.5). These differences can potentially be attributed to random 
fluctuations, to changes in the warfarin population or outcomes over time, to differences in 
practice patterns over time, to differences in those willing to participate, or to changes in 
recruitment strategies between the two studies. For instance, a decrease in the proportion of 
patients with atrial fibrillation as their warfarin indication could be related to some of these 
patients being treated with alternative anticoagulants, which were first approved for that 
indication. By contrast, the increase in the proportion of patients who were African American at 
these sites likely reflects recruitment strategies that were designed to increase the enrollment of 
this group in the validation cohort.  
 
These differences across sites are also reflected by varying performance of the prediction model 
across sites. For instance, the time-dependent AUC was not significantly better than chance at 
PVAMC, while it was better at the other sites. Similarly, the model could not account for the 
substantial differences in baseline risk that was observed at the three sites, with the prevalence of 
prolonged dose titration varying from 32% to 48%. Moreover, a post-hoc analysis where a 
prediction model was developed and tested using the same algorithm in the sites that were present 
in both derivation and validation cohorts showed no improvement in model performance (AUC = 
0.58; 95% CI 0.51, 0.64), confirming the changes in these same sites over time. Similarly, in 
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another post-hoc analysis, performance of the same model development algorithm in the 
validation cohort led to the inclusion of some different variables in the model—variables selected 
were age, BMI, warfarin indication, insurance status, previous warfarin use, history of heart 
failure, and history of arrhythmia—suggesting that the important predictors of prolonged dose 
titration might vary across sites. This model did not perform very well on cross-validation 
(LOOCV AUC = 0.62; 95% CI 0.58, 0.69), suggesting that it also would not perform well on 
external validation. It should also be emphasized that the broader differences among sites where 
patients receive warfarin in the clinical community would be expected to be much larger than the 
differences between our derivation and validation cohort; thus, the performance of the model in 
clinical practice could be expected to be even worse. 
 
Clinical utility of the prediction model. Attempts to quantify the clinical impact of the prediction 
model were consistent with our primary results. While the negative predictive value of the model 
for the lowest range of predicted values (< 20% probability of prolonged dose titration) was 
reasonably good at 0.87, only 2% of patients in the validation cohort actually fall into this 
category (Table 3.4). Both positive and negative predictive values were fairly poor at cut-offs that 
were more commonly observed in our cohort. This drop-off in performance may result from 
incorrectly ranking individuals in the middle of the probability distribution, which can be seen 
when plotting the observed vs predicted probabilities by risk decile (Figure 3.4). 
 
As shown in Figure 3.6, the relative utility of the current model is limited, with a maximum value 
of about 0.09 near the prevalence of the outcome. Additionally, the relative utility is negative for 
risk thresholds above 0.47, meaning that it is better to use standard warfarin therapy for all 
patients with high risk thresholds. This impression is confirmed by the related decision curve, 
which shows that the curves representing the net benefit of the prediction models are not 
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substantially higher than the curves for the strategies of using the same treatment in everyone for 
any risk threshold region (Figure 3.8). While the prediction model is unlikely to be useful 
clinically even in the regions where the relative utility is strictly positive, examination of the risk 
threshold can still be useful for clinicians. Knowing that the overall prevalence of prolonged dose 
titration is about 38%, a discussion of the relative importance financial and monitoring burdens 
with patients can help determine whether treatment with warfarin or an alternative agent is 
optimal in a given situation. For instance, if a given patient feels that the financial costs of 
alternative anticoagulant agents are worse than the monitoring burden of warfarin therapy, then 
his or her individual risk threshold would be above 50%. Since this threshold is greater than the 
38% prevalence of prolonged dose titration, it would be optimal to begin standard warfarin 
therapy in this patient. 
 
Importance of external validation. This study confirms the importance of using external 
validation when developing clinical risk prediction models. Given its importance, external 
validation is performed surprisingly infrequently, with recent evidence suggesting that only 25% 
of published research on new prediction models includes an external validation [Siontis, 
Tzoulaki, Castaldi, & Ioannidis, 2014]. Especially for complex, multifactorial outcomes like 
prolonged dose titration for patients starting warfarin, overall prevalence and the importance of 
different predictors are likely to vary substantially across clinical sites, and even change over 
time. While statistical methods such as cross-validation can help, external validation remains the 
gold standard for determining whether a prediction model will be useful in clinical practice. 
 
Conclusions. In conclusion, our prediction model for prolonged dose titration in patients starting 
warfarin is unlikely to be useful in clinical practice. Moreover, we suspect that this outcome and 
others like it will be difficult to predict using traditional clinical or genetic risk factors, as their 
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relationship to the outcome will likely vary substantially across clinical sites. More accurate 
prediction of prolonged dose titration will likely require researchers to better define and measure 
the social, behavioral, and access-related factors that are probably more directly related to the 
outcome. In the absence of risk prediction, clinicians should consider the relative importance of 
monitoring and financial burdens for their patients when deciding which type of anticoagulation 
therapy to begin.  
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CHAPTER 4. IMPROVING CLINICAL PREDICTION MODEL 
TRANSPORTABILITY WITH SEQUENTIAL UPDATING OF MIXED-
EFFECTS MODELS 
 
Brian S Finkelman, Benjamin French, and Stephen E Kimmel 
 
 
ABSTRACT 
Clinical prediction models often fail to generalize across clinical sites outside of those in which 
the model was derived, and they tend to lose their accuracy over time. These problems have been 
categorized under the umbrella term of poor model transportability. We propose a general 
strategy of sequential updating of mixed-effects models as a mechanism to overcome the problem 
of poor transportability. We examine the potential gains in prediction accuracy for this strategy 
through a simulation study in which poor transportability is modeled as clinic-specific differences 
in the prevalence of the outcome and the association between predictors and the outcome. We 
then test whether the sequential model updating approach is robust to several types of model 
misspecification. 
 
BACKGROUND 
Clinical prediction model transportability. It is well established that clinical prediction models 
often suffer from the problem of the poor generalizability [König, Malley, Weimar, Diener, & 
Ziegler, 2007]. In other words, models that perform well in the datasets in which they were 
derived, measured either by model calibration or discrimination, often perform worse when tested 
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in other settings. Generalizability of prediction models has been previously described as 
encompassing two major components: reproducibility and transportability [Justice et al., 1999]. 
Reproducibility of prediction models can be thought of as the ability of the model to perform well 
in repeated samples from the same population as the one that yielded the original derivation 
sample, while transportability refers to the ability of the model to perform well in samples drawn 
from different but plausibly related populations to the one that yielded the original derivation 
samples. These plausibly related populations could differ from the original population based on 
changes over time, geography, clinical setting, and definitions of predictors or outcomes, among 
other things. 
 
Many statistical methods have been developed to help address the problem of model 
reproducibility, such as Bayesian model averaging [Hoeting et al., 1999], bootstrap aggregation 
or bagging [Breiman, 1996], and a variety of methods for cross-validation [Borra & Di Ciaccio, 
2010]. Broadly speaking, these methods tend to address the problem of model overfitting. 
However, poor transportability of a prediction model often occurs because of a problem of 
underfitting rather than overfitting [Justice et al., 1999]. Underfitting occurs when important 
predictors are either unknown, misspecified, or not included in the original model, and model 
performance degrades when tested in new populations with a different conditional prevalence of 
those predictors. As a result, it is much more difficult to find statistical solutions to problems of 
transportability using the derivation sample, because by definition, the model would need to be 
tested on a sample with a different empirical distribution from the derivation sample in order to 
determine its transportability. 
 
Utility of clinical prediction models is hampered by concerns about poor transportability. Despite 
the adoption of prediction models in clinical practice, there are often major concerns about model 
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generalizability and transportability in many clinical scenarios. For instance, the American Heart 
Association (AHA) and the American College of Cardiology (ACC) released updated cholesterol 
management guidelines in November 2013 that were heavily based on individuals’ predicted 10-
year risk of cardiovascular events [Stone et al., 2014]. These guidelines drew almost immediate 
criticism because of concern about over-prediction of risk related to the particular cohorts used to 
develop the prediction model [Ridker & Cook, 2013]. Specific examples of validated prediction 
models failing to generalize to different populations have been documented, as well. For example, 
the EuroSCORE model, which was developed in European populations to predict 30-day 
mortality in patients undergoing cardiac surgery, failed to generalize to Australian surgical 
patients [Yap et al., 2006], and, even with the European population, proved inaccurate over time, 
over-predicting risk in contemporary practice [Hickey et al., 2013]. In another example, a clinical 
prediction rule for predicting deep vein thrombosis (DVT) performed well in the secondary 
referral patient population in which it was developed, but failed to generalize to a primary care 
setting [Oudega et al., 2005]. Furthermore, this problem is likely even more widespread than what 
has been directly documented in the literature because of the many clinical outcomes that are 
known to vary substantially across clinical sites, including readmission after hospitalization for 
heart failure [Ross et al., 2008], mortality following surgery for colorectal cancer [Schootman et 
al., 2014], graft failure after liver transplantation [Asrani et al., 2013], and medication adherence 
rates among diabetes patients [Sherman et al., 2011]. As a result, generally applicable methods to 
improve the transportability of clinical prediction models could have a large practical impact on a 
wide range of areas in clinical medicine. 
 
Improving prediction model transportability with sequential model updating. Generalized linear 
mixed-effects models, also known as longitudinal or hierarchical models, are well-established in 
the literature for accounting for clustered observations, such as would occur when patients at 
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specific clinical sites are more similar to each other than to the overall population, in the context 
of explanatory models [Fitzmaurice, Laird, & Ware, 2011]. However, their utility for improving 
the transportability of prediction models is less clear, because predictions on novel clusters are 
based on the hypothetical mean cluster. As a result, there is no heterogeneity across clusters for 
out-of-sample predictions, even though the model is technically capable of allowing for such 
heterogeneity. Thus, any improvement in prediction accuracy that results from using mixed-
effects models is generally because of shrinkage effects, rather than incorporating knowledge 
about cluster-specific differences. 
 
One potential approach to the problem of prediction in novel clusters is sequential model 
updating. Under sequential updating, predictions are made on individuals using the best available 
model at that time. Then, when their outcome data become available, they are systematically 
incorporated back into the model. As a result, novel clusters become incorporated into the data 
sample over time, allowing for predictions that account for cluster-specific differences. In 
practice, sequential model updating would likely involve incorporating the prediction model into 
an electronic health records system (EHR) that is integrated across multiple clinical sites, so that 
outcome data could be automatically captured and incorporated into the model. However, the 
expected improvement in prediction accuracy that would be achieved through sequential model 
updating remains unknown. Thus, given the large upfront financial costs and logistical challenges 
of implementing such a system, it is important to quantify these potential gains, as well as the 
conditions under which these gains can be maximized. 
 
Simulation study. We sought to quantify the potential improvement in prediction accuracy that 
might be expected with sequential model updating using a simulation study. Briefly, we 
simulated a population of patients who are clustered in different clinics. These patients were 
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randomly split into derivation and validation cohorts. Standard, non-updating prediction models 
were built in the derivation cohort and then tested in the validation cohort. The same models were 
then allowed to update periodically to see whether prediction accuracy improved. This process 
was then repeated 1,000 times to assess the variability of the results. Finally, the sensitivity of the 
results to changes in the value of parameters for the data-generating process was assessed. 
 
METHODS 
Overview. In our simulation, we aimed to develop a model to predict the outcome Yij, which 
represents a generic, continuous clinical outcome for patient j at clinic i. Yij is dependent on X1ij, a 
known patient-level predictor; X2ij, an unknown patient-level predictor; and Ni, the size of the 
clinic. Note that X1ij and X2ij can also be interpreted as linear combinations of important 
predictors, rather than just a single predictor. Clustering of the outcome is induced by a clinic-
level random intercept b0i and random slopes b1i and b2i. From 500 total clinics in the population, 
20 were randomly selected to make up the “derivation” cohort. Using the derivation cohort, we fit 
both updating and non-updating versions of models with fixed effects only, as well as those with 
random intercepts and random slopes. These models were then tested on the remaining clinics, 
which comprised the “validation” cohort. For each combination of parameter values, the 
simulation was run 1,000 times to estimate the degree of variability in the results. All simulations 
were performed using R 3.1.1 [R Development Core Team, 2014]. 
 
Mixed-effects modeling. Generalized linear mixed-effects models account for clustering in the 
outcome by treating some model parameters as random, rather than fixed across the population. 
These models typically follow the form: 
  (   )            , (1) 
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where  (   ) is a function of the outcome for individual j at clinic i,   is a vector of fixed effects, 
   is a vector of random effects,     is a vector of residual errors, and   and   are observed design 
matrices relating to the fixed and random effects, respectively [Fitzmaurice et al., 2011]. Random 
effects are typically modeled parametrically as  (   ), where   is the variance-covariance 
matrix. Use of this parametric structure for the random effects is typically more efficient than 
cluster-level fixed effects, making it especially useful in settings where there are a large number 
of clinical sites. 
 
Sequential model updating. The primary advantage of combining a sequential model updating 
approach with generalized mixed-effects models is that it allows the model to automatically 
calibrate to local conditions, thus improving the transportability of the model, without the need to 
recruit additional cohorts for constructing and validating a prediction model at each individual 
site. Additionally, predictions at individual sites are able to “borrow strength” from data at other 
sites to avoid the overfitting that might occur if separate models were fit at each site. One method 
of achieving model updating that has been studied in the literature is dynamic logistic regression, 
in which posterior values for Bayesian model parameters at time t are used to construct priors at 
time t + 1, when new data have become available [McCormick, Raftery, Madigan, & Burd, 
2012]. However, there are a number of approaches to estimation that could be used to achieve 
model updating; in this simulation, we are focusing on the simple method of re-fitting the original 
model at time t + 1, after incorporating additional data from the predictions that have been made 
since time t. This choice in estimation allows for a more direct comparison of updating and non-
updating models, because all other features of the models are identical.  
 
Data-generating process. For all simulations, we first generated a population of 500 clinics, each 
with Ni patients, where:  
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     ⌈   (     
 )⌉. (2) 
The log-normal distribution ensures that there are a large number of smaller clinics, with a small 
number of very large clinics. The value for   , where exp(  ) is equivalent to the median clinic 
size, was fixed at ln(65), while the value for    was fixed at ln(2), in order to ensure a range of 
clinic sizes of approximately 10 to 500 patients. These values were thought to be reflective of a 
typical clinical scenario. 
 
Next, clinic-level random intercepts and slopes were generated from a multivariate normal 
distribution, as follows: 
 {           }  (   ), (3) 
where b0i is the random intercept, b1i is the random slope for X1ij, and b2i is the random slope for 
X2ij, and the variance-covariance matrix is: 
   [
  
           
       
      
            
 
]. (4) 
The correlation between the random intercept and random slopes,  , was fixed at a moderate 
value of 0.3, which was felt to be similar to what might be observed in practice. However, 
sensitivity analyses demonstrated that the results were insensitive to increases or decreases in the 
value of the correlation (data not shown). Additionally, we determined that having the correlation 
between the random slopes differ from the correlation between the random intercept and random 
slopes would not have a substantial impact on the results (data not shown), so the same value for 
all correlations was used for model simplicity. After clinic-level random effects were generated, 
patient-level variables were generated. First, X1ij and X2ij were generated as (   ) variables. The 
variance was fixed at 1 for all parameter combinations in order to provide a reference point for 
easier interpretation of the values of other parameters. We varied   
  and   
  in order to determine  
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the impact of different relative strengths of clinic-level heterogeneities, compared to patient-level 
factors. 
Then, the outcome Yij was generated as: 
        (      )     (      )       (  )     , (5) 
where     are independent errors distributed as  (    
 ) and the value of   
  was chosen such 
that the error terms comprise 20% of the total variance in Yij. Clinic size is associated with the 
outcome through the function f, with: 
 (  )   (  (  )    (  )̅̅ ̅̅ ̅̅ ̅̅ ), (6) 
where   is a scaling factor such that  (  )  (   ). The value for    is fixed at 1 across all 
simulations, so that    and   gain the interpretation of the impact of X2ij and clinic size on the 
outcome, respectively, relative to the impact of X1ij. Note that the overall intercept across all 
clinics,   , was defined as equal to 0 and is thus not included in Equation 5. The data-generating 
process is summarized in Figure 4.1. 
Figure 4.1. Summary of data-generating process. Variables enclosed in squares are fully observed, 
variables enclosed in circles are unobserved, and variables enclosed in rounded rectangles are partially 
observed. 
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Parameter values. The main parameters that were varied for our simulation were   
  and   
 , 
which controlled the relative impact of patient-level factors and clinic-level heterogeneities on the 
outcome. Three values of each parameter were examined—0.5, 1, and 2 for   
 , and 0, 0.25, and 
0.5 for   
 —for a total of 9 main parameter combinations. The values of these parameters can be 
interpreted relative to the size of the variance in X1ij, which was fixed at 1. Additionally,    and   
were fixed at zero for these main parameter combinations, so that the effects of unknown patient-
level factors and clinic size on the results could be examined in isolation. When    was equal to 
zero,   
  was also set equal to zero, so that there was no effect of X2ij on Yij; when    was not 
equal to zero,   
  was set to be equal to   
 . We considered   
   ,   
      ,     , and     
to be the “base” parameter combination, and sensitivity analyses for individual parameters were 
based on this combination of parameter values. 
 
Later, we separately assessed the impact of non-zero values for    and  . Specifically, we 
examined values of √   , 1, and √  for both parameters. These values were selected for greater 
interpretability, as the relative contribution of X2 and  (  ) to the total variance in Yij was 
proportional to   
  and   , respectively. Thus, for example, when    √ , X2ij is contributing 
twice as much to the variance in Yij as is X1ij. This set of parameter values likely covers the full 
range of what could reasonably be expected in practice, given that the prediction models were 
being rigorously constructed in the first place. For this set of parameter combinations,   
  and   
  
were fixed at their base values. 
 
Finally, we assessed the impact of varying update intervals in an attempt to reflect longer time 
lags between predictions and the occurrence of the outcome that might take place in certain 
clinical scenarios, such as those with survival-type outcomes. We examined values of 250, 500, 
1,000, and 5,000 for  , the number of predictions made between rounds of updating for updating 
70 
 
models, as described below. We used   = 500 as the base value for all previously described 
parameter combinations. 
 
Prediction models. We randomly selected 20 clinics—stratified by clinic-size quintile,   
 —for 
the derivation cohort, mimicking a multi-site cohort that might be used to develop a clinical 
prediction model in practice. We selected 6 clinics from each of the bottom 2 quintiles, 3 clinics 
from each of the next 2 quintiles, and 2 clinics from the upper quintile. We then built 3 prediction 
models in the derivation cohort:  
1) a linear model,       ; 
2) a Bayesian linear mixed-effects (BLME) model,           ; and 
3) a second BLME model,     (      )    .  
BLME models were fit using restricted maximum likelihood, with non-informative flat priors for 
the fixed effects and a non-informative prior for the random effects covariance matrix based on 
the Wishart distribution. Estimation of BLME models was accomplished using the “blme” 
package in R [Dorie, 2014]. Additionally, for simulations when    , we also constructed 
versions of the above models that included   
  as a categorical fixed effect, since it was felt that 
  
  would be more likely to be observable than  (  ) in practice. 
 
All three models were tested in the validation cohort with and without sequential model updating. 
Sequential model updating was achieved by making predictions on   patients, incorporating 
outcome data on those individuals back into the derivation dataset, re-estimating the models, and 
then making predictions on the next   patients. This algorithm was repeated until predictions had 
been made on all patients in the validation cohort. For BLME models, this process was equivalent 
to adding new data, and did not affect the model priors. The order of predictions was random 
across the entire validation cohort, and each individual had an 80% chance to have his or her 
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outcome data incorporated into the updating algorithm. We chose 80% because it realistically 
allows for missing outcome data; this is reflective of missing outcome data that might occur when 
utilizing a sequential model updating scheme in practice, where patients might be lost to follow-
up before their outcomes are observed. 
 
Assessment of model calibration. Accuracy of prediction models was based on assessments of 
model calibration, with mean absolute error (MAE) being the primary metric [Wilmott & 
Matsuura, 2005]. MAE was calculated as: 
     
 
 
∑|   ̂     |, (6) 
where n is the total number of individuals in the validation cohort. To improve the interpretability 
of the results, we constructed a new metric, the “relative improvement” (RI) in MAE, for each 
model as: 
    
      
     
, (7) 
where    refers to the mean absolute error for the intercept-only model, as fit in the derivation 
set, and    refers to the mean absolute error for the “true” model, which was considered to be the 
model in Equation 4, minus the error term. Thus, the RI will typically range from 0 to 1 and can 
be interpreted as the improvement of the current model over the intercept-only model, relative to 
the improvement that would have been seen with the “true” model. Negative values for RI 
indicate that the given model is worse than predicting the average value in everybody. 
 
RESULTS 
Population characteristics. There were 41,576 (SD 1,465) patients in the total simulated 
population, on average, with 1,276 (SD 118) patients in the derivation cohort. Clinics ranged in   
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Table 4.1. Clinic size distribution in the simulated population. 
size from 9 to 549 patients, on average. The median clinic had 66 patients, and 67% of patients 
were in clinics in the top two quintiles of clinic size. Other characteristics of the distribution of 
clinic size, which are reflective of the log-normal distribution selected, are shown in Table 4.1. 
The effect of varying   
  and   
  on clinic-level clustering is shown in Figure 4.2; as expected, 
increasing   
  , which represents the variance of the random intercepts, tended to yield greater 
vertical displacement among the slopes, while increasing   
 , which represents the variance of the 
random slopes, led to a more defined fanning pattern. 
 
Main parameter results. As can be seen in Table 4.2, the prediction models explained a 
substantial amount of the variance in the derivation cohort, ranging from an r2 of 0.25 to 0.80, 
depending on the model and parameter combination. Furthermore, the addition of random effects 
consistently led to dramatic improvements in the model r2 in the derivation cohort, creating the 
initial appearance of improved model performance. However, because all out-of-sample 
predictions are made assuming that new clinics have the mean value for their random intercept 
and slope, the addition of random effects led to virtually no improvement in the accuracy of 
predictions in the validation cohort, with mean RI at 33% to 34% for all non-updating models for 
the base parameter combination. In contrast, use of sequential model updating led to dramatic 
improvements in RI for both BLME models, across all parameter combinations tested (Figure 
4.3).  
Clinic-size quintilea,b 0–20% 20–40% 40–60% 60–80% 80–100% 
Minimum number  
of patients in quintile 
9 (2) 37 (2) 55 (2) 78 (3) 117 (5) 
Percent of population  
in quintile 
6.1 (0.3) 10.9 (0.5) 15.8 (0.6) 23.0 (0.6) 44.2 (1.2) 
aResults are presented as mean (SD) across 1,000 simulations. 
bClinic size distribution is not affected by varying the value of the main parameters. 
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Table 4.2. Mean r2 for non-updating models in derivation cohort across all main parameter combinations. 
  
 Model   
     a   
    a   
    a
      0.42 (0.11) 0.34 (0.10) 0.25 (0.09) 
0.5           0.61 (0.08) 0.64 (0.07) 0.68 (0.07) 
    (      )    0.80 (0.04) 0.80 (0.04) 0.79 (0.04) 
      0.47 (0.09) 0.38 (0.08) 0.27 (0.08) 
0.25           0.69 (0.06) 0.71 (0.05) 0.73 (0.06) 
    (      )    0.80 (0.04) 0.80 (0.04) 0.79 (0.04) 
      0.55 (0.06) 0.42 (0.06) 0.29 (0.06) 
0           0.80 (0.02) 0.79 (0.03) 0.79 (0.04) 
    (      )    0.80 (0.02) 0.80 (0.03) 0.79 (0.04) 
aResults presented as mean (SD) over 1,000 simulations. 
Figure 4.2. Effect of   
  and   
  on clinic-level clustering. Each point represents an individual patient at 
one of the 20 clinics in the derivation cohort for a single simulation run. Lines represent the actual 
relationship between X1ij and Yij at each derivation clinic. The center figure represents the base 
parameter combination. 
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Figure 4.3. Relative improvement in MAE for both updating and non-updating models across all main 
parameter combinations. Plots show the density of values for relative improvement in MAE across 1,000 
simulations, with horizontal bars representing the mean value. 
As can be seen in Figure 4.4, gains in prediction accuracy from sequential model updating were 
seen across all clinic-size quintiles, although the greatest improvement was seen in the largest 
clinics. This pattern likely reflects the fact that improvements from updating were seen relatively 
rapidly, with approximately 90% of the total gains in predictive performance for both BLME 
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models occurring after about 10 predictions at a given clinic (Figure 4.5). Because there were 480 
clinics in the validation cohort and the model was updated after every 500 predictions, model 
updates occurred after almost every prediction, on average, especially at smaller clinics. 
Effect of model misspecification. When there was an unknown patient-level factor impacting the 
outcome (i.e.     ), sequential model updating was less effective (Figure 4.6). However, 
updating models still were more accurate than non-updating models for all values of   . Having 
the outcome be dependent on clinic size (i.e.    ) led to worse performance of non-updating 
BLME models, with these models performing worse than intercept-only models with large values 
of   (Figure 4.7). However, updating BLME models showed no drop-off in prediction accuracy 
with non-zero values of  . Inclusion of clinic size quintile,   
 , as a categorical fixed effect led to 
marked improvement in non-updating BLME models and even slight improvement in updating 
BLME models, on average (Figure 4.8). 
Figure 4.4. Relative improvement in MAE by clinic-size quintile. Plots show the density of values for 
relative improvement in MAE across 1,000 simulations, with horizontal bars representing the mean value. 
These results are for the base parameter combination. 
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Figure 4.5. Rate of improvement in prediction accuracy at a given clinic. This plot shows the mean 
relative improvement in MAE for prediction j at clinic i, across 1,000 simulations. These results are for the 
base parameter combination. 
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Figure 4.6. Effect of    on model prediction accuracy. Plots show the density of values for relative 
improvement in MAE across 1,000 simulations, with horizontal bars representing the mean value. The 
parameters for   
  and   
  are fixed at their base values. Note that the relative contribution of X2ij to the 
total variance in Yij, compared to X1ij, is equal to   
 . 
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Figure 4.7. Effect of   on model prediction accuracy. Plots show the density of values for relative 
improvement in MAE across 1,000 simulations, with horizontal bars representing the mean value. The 
parameters for   
  and   
  are fixed at their base values. Note that the relative contribution of  (  ) to the 
total variance in Yij, compared to X1ij, is equal to  
 .
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Figure 4.8. Effect of   on prediction accuracy for models that include   
 . Plots show the density of values 
for relative improvement in MAE across 1,000 simulations, with horizontal bars representing the mean 
value. All models include   
 , which represents clinic-size quintile, as a categorical fixed effect. The 
parameters for   
  and   
  are fixed at their base values. Note that the relative contribution of  (  ) to the 
total variance in Y, compared to X1, is equal to  
 . 
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Effect of varying the update interval. Results were fairly insensitive to changes in  , the update 
interval. Even when   = 5,000, or about 12.5% of the validation cohort, prediction accuracy in 
updating BLME models was not substantially decreased (Figure 4.9). Furthermore, prediction 
accuracy was consistent across all quintiles of clinic size with varying values of   (data not 
shown). Finally, the rate of improvement in prediction accuracy only showed a notable decrease 
when   = 5,000, when about 90% of total gains in prediction accuracy for both BLME models 
occurred after about 20 predictions at a given clinic (Figure 4.10). Note that this value for   
corresponds to a highly unlikely scenario where the model can only be updated about 8 times 
over the course of using the model on a population of about 40,000 individuals. 
 
DISCUSSION 
Overview. In this simulation study, we sought to quantify the potential effect of sequential model 
updating on the accuracy of clinical prediction models. Sequential updating of BLME models led 
to uniform improvement in prediction accuracy across all parameter combinations examined. 
Thus, it seems quite likely that substantial gains in the transportability of clinical prediction 
models could be achieved through sequential updating of models that account for clinic-specific 
heterogeneities, including differences in the mean level of the outcome as well as differences in 
the association between known predictors and the outcome. However, the extent of the gains in 
prediction accuracy from updating varied depending on the degree of misspecification of fixed 
effects, indicating that use of sequential model updating will likely be more useful in clinical 
scenarios where such misspecification can be minimized. 
 
Impact of sequential model updating. Sequential model updating did not substantially improve 
prediction accuracy with the linear model, performing similarly to all non-updating models.  
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Figure 4.9. Effect of the update interval,  , on model prediction accuracy. Plots show the density of values 
for relative improvement in MAE across 1,000 simulations, with horizontal bars representing the mean 
value. All other parameters are fixed at their base values. 
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Figure 4.10. Effect of the update interval,  , on the rate of improvement in prediction accuracy at a given 
clinic. This plot shows the mean relative improvement in MAE for prediction j at clinic i, across 1,000 
simulations, for different values of  . All other parameters are fixed at their base values. 
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As a result, flexible models with random effects were needed to account for the heterogeneities 
across clinics. The accuracy of non-updating models decreased with increasing values of   
  and 
  
 ; in short, greater heterogeneity across clinics led to worse performance for models that did not 
take these differences into account. By contrast, updating BLME models showed greater 
improvement in prediction accuracy when a larger proportion of the variation in the outcome was 
explained by clinic-level heterogeneities. The BLME model with a random intercept showed 
improved prediction accuracy with increasing values of   
 ; however, its performance deteriorated 
with higher values of   
 . This deterioration in accuracy with larger random slopes is not 
surprising, because this model had no way to account for the random slopes that were present in 
the data structure. Even so, the model was able to use its random intercept to account for a large 
enough amount of inter-clinic variability to provide uniform improvement over non-updating 
models and the linear updating model. 
 
The BLME model with both a random intercept and random slope was nearly as accurate as the 
“true” model across all main parameter combinations, with a mean RI ranging from 94 to 96%. 
This was because the model was essentially equivalent to the data-generating model in these 
cases, and updating occurred fast enough that predictions on most individuals in the validation 
cohort were made with a fully calibrated model. Indeed, about 90% of the gains in prediction 
accuracy were seen by about the 10th patient at a given clinic, so even small clinics were able to 
see benefits from sequential model updating, and the majority of predictions at large clinics were 
made with an accurate estimate of clinic-specific random effects. This rapid improvement in 
prediction accuracy was largely sustained even with higher values of  , so overall prediction 
accuracy in the validation cohort was preserved even when models were updated less frequently. 
It should also be noted that this high level of prediction accuracy was sustained even when there 
was no random slope in the data-generating process (  
  = 0). Thus, there was not really much 
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downside to having an unnecessary random slope in the updating model, while having only a 
random intercept when the data-generating process included both a random intercept and a 
random slope led to decreased prediction accuracy. 
 
Additionally, the variance of RI values across simulations tended to be lower in updating models 
than in non-updating models. The variance in prediction accuracy decreased with each additional 
random effect in the model, as well. This speaks to another important feature of sequential model 
updating, which is the ability to overcome sampling bias to produce models that perform more 
consistently. In the non-updating models, the prediction accuracy was largely dependent on 
whether the clinics that comprised the derivation cohort happened to be representative of the 
overall population. In simulations where estimates of    and    were very different from their 
true values due to random sampling, prediction accuracy for non-updating models in the 
validation cohort tended to be worse (Figures 4.11–4.13). However, sequentially updating models 
were able to overcome initial sampling bias by improving model calibration over time. 
 
Impact of model misspecification. When an unknown patient-level factor was added to the data 
structure (    ), updating BLME models had a decrease in prediction accuracy; however, they 
still performed better than non-updating models for all values of   . In short, it is still important 
to be diligent when selecting covariates and their specifications for a sequentially updating model, 
as models that are closest to the true data-generating process will still perform the best. However, 
most realistic clinical scenarios involve unknown predictors and misspecification, so the fact that 
sequential model updating still led to improvements in prediction accuracy under these conditions 
suggests that it may be a useful strategy in the real world. 
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Figure 4.11. Relationship between bias in estimated model coefficients and prediction accuracy for the 
linear model. Each point represents one of 1,000 total simulations for the base parameter combination, and 
best fit lines are shown in red. The left panel shows the bias in the estimated intercept from the derivation 
cohort compared to the true value in the overall population, while the right panel shows this bias for the 
estimated slope. 
Figure 4.12. Relationship between bias in estimated model coefficients and prediction accuracy for the 
BLME model with random intercept. Each point represents one of 1,000 total simulations for the base 
parameter combination, and best fit lines are shown in red. The left panel shows the bias in the estimated 
intercept from the derivation cohort compared to the true value in the overall population, the middle panel 
shows this bias for the estimated slope, and the right panel shows this bias for the estimated variance of the 
random intercepts. 
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Figure 4.13 Relationship between bias in estimated model coefficients and prediction accuracy for the 
BLME model with random intercept and slope. Each point represents one of 1,000 total simulations for the 
base parameter combination, and best fit lines are shown in red. Starting from the top left panel and 
moving in clockwise fashion, the panels show the bias in the estimated intercept, slope, variance in the 
random slopes, and variance in the random intercepts, as compared to the true value in the overall 
population. 
Clinic size or volume may be related to outcomes in a number of clinical scenarios, such as 
hospital mortality rates for acute myocardial infarction or surgical mortality rates [Birkmeyer et 
al., 2002; Silber et al., 2010]. While other clinic-level effects can be accommodated by random 
intercepts and slopes, we were concerned that clinic size might behave differently because it is 
directly related to the probability of observing the data in the first place. Larger values of   led to 
worse performance of non-updating BLME models, while updating BLME models showed no 
deterioration in performance. In non-updating BLME models, the effect of sampling bias was 
actually amplified because differences due to clinic size were incorporated into the model as 
random effects, with greater bias in the estimated random effects covariance matrix leading to 
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worse prediction accuracy (Figures 4.14 and 4.15). However, in updating models, these initial 
biases were diminished over time because the model was continually being calibrated to the 
overall population, such that the majority of predictions were unaffected by the initial biases. As a 
result, inclusion of   
  was required to improve the accuracy of non-updating BLME models, but 
not practically necessary in the case of updating BLME models. These results also speak to the 
general robustness of sequentially updating models that account for clinic heterogeneities; while 
correct specification is still better, misspecification is not nearly as costly as it is with non-
updating models. 
 
Challenges to incorporating sequential model updating in practice. Implementation of sequential 
model updating in practice will likely involve many logistical and analytical challenges. In order 
to work well, prediction models will likely need to be integrated into EHR systems, so they will 
be able to automatically extract covariate data to make an initial prediction, and then 
automatically extract outcome data to use for model updating. Furthermore, in order to 
accommodate heterogeneities across sites, the EHR will need to either be standardized across all 
of the sites, or compatible enough to allow for communication of data. Additionally, the data 
storage and security requirements for large amounts of data across multiple sites will likely be 
quite complex. Certain analytic strategies—such as Bayesian dynamic regression, where posterior 
distributions are estimated from dynamic priors in a fully online fashion [McCormick et al., 
2012]—could greatly reduce the data storage requirements, and, accordingly, the data security 
concerns. However, more work is needed to determine the trade-offs in prediction accuracy that 
might accompany this approach under certain scenarios. Finally, there will need to be a concerted 
effort to communicate the effectiveness of this approach to the clinical community in order to 
foster the necessary level of trust to overcome initial financial and logistical hurdles. 
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Figure 4.14. Relationship between bias in estimated model coefficients and prediction accuracy for the 
BLME model with random intercept, with clinic size influencing the outcome. Each point represents one of 
1,000 total simulations with  √ , and best fit lines are shown in red. The left panel shows the bias in the
estimated intercept from the derivation cohort compared to the true value in the overall population, the 
middle panel shows this bias for the estimated slope, and the right panel shows this bias for the estimated 
variance of the random intercepts. 
Figure 4.15 Relationship between bias in estimated model coefficients and prediction accuracy for the 
BLME model with random intercept and slope, with clinic size influencing the outcome. Each point 
represents one of 1,000 total simulations with  √ , and best fit lines are shown in red. Starting from the
top left panel and moving in clockwise fashion, the panels show the bias in the estimated intercept, slope, 
variance in the random slopes, and variance in the random intercepts, as compared to the true value in the 
overall population. 
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The analytic challenges involved in sequential model updating are also likely to be quite 
complex. Missing data, both for covariates and outcomes, will be an important issue to resolve, as 
standard methods, such as multiple imputation [Groenwold, Donders, Roes, Harrell, & Moons, 
2012; Moons, Donders, Stijnen, & Harrell, 2006], may be difficult to implement in the context of 
a dynamic system. As a result, efforts to jointly model the updating process along with the 
prediction model itself, analogous to methods for jointly modeling longitudinal and competing 
risks data [Li, Elashoff, & Li, 2009], may be required. Alternatively, use of missing indicators 
may be more useful than with standard models [van der Heijden, Donders, Stijnen, & Moons, 
2006], because these parameters would be allowed to calibrate to the population over time. 
However, further studies are needed to answer these questions empirically. Other important 
analytic issues that would need to be resolved include how to incorporate new predictors or 
specifications into a sequentially updating model; how much to weight historical data in a 
population that is changing over time; how best to account for time lags between making 
predictions and obtaining outcome data; and how to determine whether a model is not performing 
well enough at a given site and needs to be replaced with a separate, newly derived model. 
 
Study limitations. Although our simulation was based on a hypothetical predictor and outcome 
variable, we tried wherever possible to mimic situations that might occur when developing and 
utilizing a typical clinical prediction model. For instance, we utilized a log-normal distribution for 
clinic size, so that there would be a larger number of small clinics than large clinics, and we 
generated the derivation cohort to be similar in size and composition to what might be found in a 
large multi-center cohort study. We also excluded some patients from contributing data to 
updating models, to reflect the loss to follow-up that might occur in clinical practice. Finally, we 
examined scenarios where the model was not correctly specified, which are likely to occur in 
real-world applications. 
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Despite these efforts, there are a number of limitations to our model. For instance, we did not 
examine scenarios where heterogeneities across clinics were not normally distributed. It is 
possible that standard BLME models might not perform as well in this scenario, leading to a 
model that was less calibrated to local conditions, even after updating. However, research 
studying the impact of misspecified parameterization of random effects on prediction accuracy 
suggests that the standard multivariate normal assumptions should be reasonably robust 
[McCulloch & Neuhaus, 2011]. Additionally, we assumed in our simulation that outcome data 
that was not available for updating was missing completely at random, which may not hold in 
practice. Future studies are needed to determine whether the prediction accuracy of sequentially 
updating models will be worsened in scenarios where the probability of obtaining outcome data 
for updating is dependent on model covariates or, especially, the outcome. 
 
We attempted to cover a reasonable range of parameter values in our analysis; however, it is 
possible that our results will not extrapolate to values outside of the tested ranges. Additionally, 
to reduce computational burdens, we focused on a simplistic model: a single continuous predictor 
and a continuous outcome. Clearly, clinical prediction models in the real world will have multiple 
covariates, and many will have more complex outcomes. The precise gains in prediction accuracy 
from sequential model updating will likely vary depending on the particular structure of the data 
in question. Finally, sequential model updating in practice will have to deal with a lag between 
when predictions are made and when outcomes are observed. It is possible that long lag periods 
relative to the frequency of updating will decrease the rate at which prediction accuracy 
improves. As a result, sequential model updating may be less useful for prediction models with 
long lag times, especially at smaller clinics or in rapidly changing populations. We attempted to 
assess the sensitivity of our results to long lag times by varying the update interval,  , and large 
improvements in prediction accuracy with updating BLME models were still seen even at the 
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highest values of  . Even with these positive results, though, the exact effect of time lags on the 
performance of sequentially updating models will need to be formally addressed in future 
research. Despite these limitations, we are confident that sequential model updating will prove to 
be a useful approach for a broad set of clinical scenarios. 
 
Future directions. Many of the limitations and challenges discussed above provide an excellent 
framework for future research in this area. More simulations are needed to test the performance of 
sequential model updating in the context of clustered populations that change dynamically over 
time, which will be more reflective of actual patient populations. Additionally, more rigorous 
study of time lags in outcome variables and approaches to handling missing data are needed. 
Furthermore, more explicit comparison of different specific modeling approaches, such as formal 
Bayesian dynamic approaches [McCormick et al., 2012], model averaging techniques [Raftery, 
Gneiting, Balabdaoui, & Polakowski, 2005], non-parametric strategies [Ryu, Li, & Mallick, 
2011], and machine learning methods [Hastie et al., 2009] are needed. Finally, these approaches 
will need to be tested in a variety of empirical studies to determine the extent to which theoretical 
gains are likely to be realized in practice. 
 
Conclusions. In conclusion, sequential updating of models that accommodated clinic-level 
differences led to improved prediction accuracy in the overall population. The extent of the 
improvement in prediction accuracy that was observed with updating mixed-effects models 
depended on the relative impact of clinic-level and patient-level factors on the outcome as well as 
the degree of model misspecification; however, updating mixed-effects models were uniformly 
superior to non-updating models as well as updating models with only patient-level fixed effects. 
Gains in prediction accuracy tended to occur rapidly, leading to improvements at small clinics as 
well as large clinics. While there are many logistical and analytical questions to resolve, the 
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potential for a sequential model updating approach to improve the transportability of clinical 
prediction models seems quite promising.  
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CHAPTER 5. CONCLUSIONS 
 
In Chapter 2, we found that baseline behavioral factors, health care utilization, and health quality 
were associated with longer time to maintenance dose in patients initiating warfarin therapy, 
while in Chapter 3, we discovered the difficulty of developing a model to predict prolonged dose 
titration in these patients. Our results in Chapter 4 suggested that sequential model updating of 
mixed-effects models can lead to substantial improvement in prediction model transportability. In 
addition to these specific results, however, a major focus of this dissertation was using warfarin 
response as an example of therapeutic effectiveness research in general. Thus, while the studies in 
Chapters 2 and 3 are designed to address specific questions about patients initiating warfarin 
therapy, the lessons gleaned from these studies can apply to the field of therapeutic effectiveness 
research more broadly. Similarly, the methods examined in Chapter 4 would be expected to 
extend beyond models of therapeutic effectiveness to clinical prediction models more generally. 
 
In Chapter 2, we examined the genetic, clinical, and social factors associated with time to 
maintenance dose (TTM) for patients starting warfarin therapy. The results highlight the 
importance of considering non-genetic factors when studying outcomes related to anticoagulation 
control. While most of the previous research on TTM had focused on genetic variants that have 
been previously found to affect the required therapeutic dose of warfarin [Cavallari et al., 2011; 
Higashi et al., 2002; Jorgensen et al., 2009; Limdi et al., 2008; Meckley et al., 2008], none of the 
genetic variants we examined were significantly associated with TTM. Instead, TTM appeared to 
be more related to baseline behavioral factors, health care utilization, and health quality. Of 
particular importance was the finding that having previously been on warfarin was associated 
with longer, rather than shorter, TTM. This new finding suggests that clinicians should be just as 
vigilant in monitoring these patients, even though they have more experience with warfarin 
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therapy. These findings are salient for the broader field of therapeutic effectiveness research, as 
well. In an era of “personalized medicine” [Crews, Hicks, Pui, Relling, & Evans, 2012], it is 
important that research on the impact of genetic factors on the effectiveness of a given therapy 
not come at the expense of research on non-genetic factors, which may be just as important, if not 
more so, in clinical practice. 
 
When conducting this study, we had hoped to identify potential targets for future interventions for 
improving TTM in patients on warfarin therapy by examining the effect of post-initiation factors, 
such as changes in interacting medications or changes in diet. Our results were disappointing 
here, because none of the post-initiation factors examined were significantly associated with 
TTM. These results further suggested that changes likely did not occur frequently enough in the 
early stages of warfarin therapy to affect TTM or that clinicians responded to these changes with 
appropriate dose changes. However, it is still possible that these factors might be more important 
for determining anticoagulation control in patients in the maintenance phase of therapy, when 
monitoring is less frequent and dose titration is not active. Future research on this topic will need 
to ensure correct specification of time-varying factors to avoid immortal time bias as well as 
adjustment for variable INR monitoring frequency to avoid interval censoring bias. 
 
In Chapter 3, we developed and externally validated a model to predict prolonged dose titration in 
patients initiating warfarin therapy. While the model developed appeared to perform well in the 
derivation cohort, even when assessed using cross-validation, it did not perform as well in the 
external validation cohort. As a result, it is unlikely that the model will be useful in clinical 
practice. Post-hoc analyses suggested that model performance varied substantially across clinical 
sites, with marked differences in the AUC among the anticoagulation clinics in the validation 
cohort. These sites differed from each other in terms of outcome prevalence and patient 
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characteristics, and the most important predictors of prolonged dose titration in the validation 
cohort were somewhat different from the derivation cohort. Although the prediction model itself 
will not be useful for clinical practice, our results offer an important cautionary tale on the 
essential need for external validation when developing prediction models.  
 
Furthermore, the rigorous decision-theoretic approach that we used to examine the clinical utility 
of our model will still be useful, both to clinicians and to future researchers. An understanding of 
the risk threshold can help clinicians formally think about the relative costs of financial and 
monitoring burdens for their patients and then come to a decision about optimal treatment choice 
based on the overall prevalence of the outcome. Additionally, future prediction models on 
therapeutic effectiveness will likely be more easily incorporated into clinical practice if they can 
demonstrate their usefulness to the clinical decision-making process with metrics such as relative 
utility. More research is certainly needed to develop summary metrics of prediction model 
performance that are rooted in decision theory; it is likely that clinicians will be more trusting of 
these methods when they become simpler and more intuitive. 
 
The substantial variability in the performance of our prediction model across clinical sites in 
Chapter 3 provided an unexpectedly good motivation for the methodological work done for the 
project described in Chapter 4. Poor transportability is a pervasive problem for clinical prediction 
models, and, generally, most research has focused on developing new models or finding new 
predictors that can provide incremental improvement, without addressing the fundamental 
challenge of accounting for variability in the relationship between predictor variables and 
outcomes in different locations, across clinical domains, and over time. With recent technological 
advancement in and widespread adoption of electronic health record (EHR) systems [Kukafka et 
al., 2007], it has become easier to imagine systems that utilize EHR data to improve predictions 
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made across integrated health systems. Essentially, prediction models could be incorporated into 
an EHR system, used to make predictions on patients within that system, and then updated 
sequentially as outcome data on those patients become available. Flexible models, such as mixed-
effects models, would thus be able to use this updated information to calibrate to local conditions, 
such as individual clinics or even individual patients in some settings, over time, while using the 
data from the overall population to avoid overfitting at any one site. 
 
Because integrating a clinical prediction model into an EHR would likely involve substantial 
upfront costs, we felt it was important to quantify the potential gains in prediction accuracy that 
could be achieved by sequential model updating. We achieved this aim through a simulation 
study, presented in Chapter 4, comparing the prediction accuracy of several updating and non-
updating models for a generic clinical outcome. The results suggested that sequential updating of 
models that account for heterogeneity across clinics in mean outcome levels and predictor-
outcome associations can lead to dramatic improvements in prediction accuracy. Furthermore, 
while the extent of the gains varied depending on the degree of model misspecification—
including misspecification of the random effects structure, the presence of unknown patient-level 
predictors, and the presence of unknown or misspecified clinic-level predictors, such as clinic 
size—there were no scenarios we examined in which updating models performed worse than non-
updating models. Thus, sequential model updating has the potential to be a broadly applicable 
approach to improving clinical prediction modeling. 
 
However, there remains important methodological work to be done before sequential model 
updating approaches can be widely adopted in clinical practice. For instance, the length of time 
between when predictions are made and when outcomes are experienced could impact the 
feasibility of sequential model updating in certain clinical scenarios. Additionally, methods to 
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deal with missing data and outcome-dependent data collection will need to be tested. Different 
types of statistical models will also need to be compared based on how well they perform in an 
updating framework. Metrics to decide how to incorporate new predictors into established models 
and to determine whether stratified or unified models are needed across diverse patient 
populations will need to be developed. Finally, empirical demonstration projects are also likely to 
reveal unanticipated logistical and analytic challenges that can form the basis for future 
methodological research. All of this work will help to clarify the types of clinical situations where 
sequential model updating would be expected to be most useful and how best to implement this 
approach in practice. 
 
Ultimately, adaptation is likely to be a common theme for therapeutic effectiveness research 
moving forward. Anticoagulation research is shifting in focus from how to determine a patient’s 
warfarin dose to how best to use warfarin as one of a number of therapeutic alternatives. 
Although it proved to be less useful for predicting prolonged dose titration in patients starting 
warfarin therapy, genetic and genomic data will likely be more successful at predicting who is 
likely to respond to therapy or experience side effects for other specific conditions. In contrast, 
methods to improve medication access and adherence will likely be more important for 
conditions where genetic factors are less useful. To maximize their clinical utility, prediction 
models will need to be able to adapt to heterogeneities in patient populations and practice patterns 
in different locations as well as changes in clinical practice over time. It is our hope that the work 
in this dissertation and the work that will arise from it represent a small step toward making 
therapeutic effectiveness research more effective. 
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APPENDIX 
 
List of medications considered to interact with warfarin. Potentially interacting drugs were 
identified from the Physicians Desk Reference, Drug Facts and Comparisons 4.0, and MEDLINE 
literature searches as of the time that patients were enrolled in the study. 
 
Drug Name Drug Name (cont.) 
(CHOLESTROL LOWERING MED.) 
LIPITOR 
IMURAN 
ASTORVASTATIN INDOCIN (X 7 DAYS) 
ATORVAST ISONAL 
ATORVASTATIN KETOCONAZOLE 
ATORVASTATIN CA/LIPITOR KETOCONAZOLE (PILLS) 
ATORVASTATIN CALCIUM KETOCONAZOLE CREAM 
ATORVASTIN CALCIUM KOFECOXIB 
ATOVASTITIN CALCIUM LAMISIL 
CRESTOR LASIX 
CRESTOR/ROSAVASTATIN LASIX INCREASED 
HIGH CHOL. MED./ LIPITOR LEVAGUIN 
LESCOL LEVAQUIN 
LESCOL 20MG QD LEVAQUIN 750 
LESCOL/FLUVASTATIN LEVAQUIN/ANTIBIOTIC 
LIPITOL LEVOFLOXACIN 
LIPITOR LEVOFLOXCIN 
LIPITOR 20MG GD LEVOQUIN 
LIPITOR 40MG QD LEVOQUIN (TILL 10-16) 
LIPITOR/ATORVASTATIN CA LEVOTHROYOXINE 
LIPITOR/ATORVASTATIN CALCIUM LEVOTHYROPINE 
LIPOTON LEVOTHYROXIN 
LOSCOL LEVOTHYROXINE 
LOVASTANTIN LEXA PRO/SELECTIVE SERETONIN 
REUPTAKE 
LOVASTATIN LISINIPRIL/HCTZ/ZESTORETIC 
MEVACOR LISINOPRIL/HYDROCHLROTHIAZIDE/ZEST
ORETIC 
PRAVACAL MASOCORT AC / NASAL STEROID 
PRAVACHOL MAXIDE 
PRAVACHOL 80 MG DAILY MEDROL 
PRAVACHOL/PRAVASTATIN METHIMAZOLE 
PRAVACHOT METHIMAZOLE  THYROID 
PRAVASTATIN/PRAVACOL METHONIDAZOLE 
PRAVOCHOL METHYLPHENIDATE 
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PREVASTATIN METHYL-PREDINZONE 
PROVOCHOL/PRAVASTATIN METOLAZONE 
ROSUVASTATIN/CRESTOR METRINIAZOLE 
SIMAVASTATIN METRONIDAZOLE 
SIMVASTATIN METRONIDAZOLE X 8 WKS. 
SIMVASTATIN (ZOCOR) MOTRIN 
SIMVASTIN MULTI-SYMPTOM NON-ASPIRIN COLD 
MEDICINE 
ZOCOR NAFCILLIN 
ZOCOR 20 MG PO QD NAPROSIN 
ZOCOR/SIMVASTATIN NAPROSYN 
ZOCOR/SIMVASTIN NAPROXEN 
ZOLCOR NAPROXIN 
(CANCER TREATMENT) 
"CARBOPLATIN 
NAPROXYN 
(CHEMOTHERAPY) S-FU NASACORT 
(HYDROCODONE-APAP) NASOCORE 
(PAIN MED.) HYDROCO/APAP NASOCORT 
(TERBINAFINE) NELFINAVIR 
A.S.A. NELFINAVIRMESYLATE/NIRACEPT 
A.S.A. 81 NEOMYCIN 
ACARBASE NIZOVAL CREAM 
ACCOLATE NORVIR 
ACCURETIC OLMESARTAN 
MEDOXOMIL/HCTZ/BENICAR 
ACETAMINOPHEN OMACOR (FISH OIL) RX 
ACETAMINOPHIN OMAPRAZOLE 
ADVIL OMEGA 3 FATTY ACIDS 
ADVIL COLD PILLS OMENPRAZOLE 
ALDACTAZIDE/SPIRONOLACTONE OMEPRAZOLE 
ALDACTONE OMEPRAZOLE (GERD) 
ALEVE OMEPRAZOLE/PRILOSEC 
ALFALFA OMEPROZOLE 
ALKA SELTZER PLUS COLD MED. OMESARTAN/HYDROCHLOROTHIAZIDE 
ALLAPURINOL ORTHOTRYCYCLINE 
ALLIPURINOL OXALIPPATIN 
ALLOPURINOL OXYCODONE W/APAP 
ALLUNOPURINOL OXYCODONE/APAP 
ALLUPROPINOL PANADOL FOR COLD 
AMIADARONE PARACETAMOL 
AMIODARON PAROXETINE 
AMIODARONE PAXIL 
AMIODARONE HCL PCE 
AMIODARONE HCL. PENICILLIN (PENECILLIN) 
AMIODIONE PERCOCET 
AMIODORONE PERCOCET (OXYCODONE-APAP 
ANTIBIOTIC/METRONIDAZOLE PERCOCET PRN 
ANTIBIOTICS- PERCOCET-POSTOP PAIN 
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SULFAMETHOXOZOLE/TRIMETHOPRI
M 
ANTIDEPRESSANT-CELEXA PERCOCETS 
APA PERIOSTAT 
APA/TYLENOL PESTO-CET (PERCOCET) 
ARTHROTEK PHENOBARBITAL 
ASA PHENYTOIN 
ASA (FOR PROCEDURE) PHENYTOIN SODIUM 
ASA 81 MG PO QD PHYTONADIONE 
ASA 81MG. PIROXICAM 
ASA, 81MG PIROXICAM/FELDENE 
ASIPRIN PIROXICAM/FELDINE 
ASPIRIN PIROXICAN 
ASPIRIN (LOW DOSE) PIROXICN 
ASPRIN PLACIDEL 
AZATHIOPRINE PREDNISOLONE EYEDROPS 
AZATHIOPRINE/IMURAN PREDNISONE 
AZITHROMYCIN PREDNIZONE 
AZITHROMYCIN-ONE DOSE ONLY PREDUIBONE 
AZMACORT PREDUISONE 
BABY ASA PRILOSEC 
BACTRIM PRILOSEC 11/29-12/12/04 
BACTRIM 
SS/SULFAMETHOXAZOLE/TRIMETHO
PRIM 
PRIMIDONE 
BACTRIM/SULFAMETHOXAZOLE/TRI
METHOPRIM 
PRIOXICAM 
BACTRUM PROPAFANONE 
BENICAR PROPAFENONE 
BEXTRA PROPAFENONE (RYTHMOL) 
BEXTRA 10MG QD PROPAFENONE-RYTHMOL 
BEXTRA/VALDECOXIB PROPAFERONE 
BEXTRA/VALDECOXILO PROPANOLOL 
BIAXIN/CLARITHROMYCIN PROPANOLOL ER 
BICALURIMINE PROPOXYPHENE. 
BICALUTAMIDE PROPRANOLOL 
CAPECITABINE PROTOZONE 
CARAFATE PROXICAM/FELDENE 
CARBOPLATIN PROZAC 
CASODEX QUININE 
CASODEX/BICALUTAMIDE QUININE SULFATE 
CEFAZOLIN RANITIDINE 
CEFRIAXONE RANITIDINE HCL 
CEFTRIAXONE RANITIDUIE 
CELEBREX RANTITIDEINE 
CELEBREX 200MG REFOCOXIB 
CELEBREX/ CELECOXIB REQUIP 
CELECOXIB/CELEBREX REQUIP (RLS)/ROPINIROLE HCL 
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CELEXA REQUIP/REPINIROLE 
CHEMOTHERAPY-TAXOL REYATAZ 
CHLORPHENIRAMINE MALEATE REYATAZ (ATAZANAVIT) 
CHOLESTYR RHYTHMOL 
CIPRO RHYTHMOL 300MG TID 
CIPRO 3/29 -> 4/2/05 RIBAURIN 
CIPROFLOXACIN RIBAVIRIN 
CITALOPRAM RIFAMPIN 
CITALOPRAM HYDROBROMIDE RITALIN 
CLARITHROMYCIN RITONAVIR (NORVIR) 
CLELBREX RYTHMOL 
CLOBETASAL CREAM SANDOSTATIN 
COATED ASPIRIN SERTRALINE 
CONCERTA (PRN) SPIRONALACTONE 
CORTISONE SHOT SPIRONOLACTONE 
CORTIZONE SHOT SPIRONOLACTONE/HCTZ 
CYCLOSPORIN SULFA 
DARVOCET SULFAMETHOXAZOLE 
DARVOCET-N SULINDAC 
DECADRON SUSTIVA 
DEPAKOTE (BIPOLAR) SYNTHROID 
DETROL SYNTHROID/LEVOTHYROXINE 
DETROL-LA SYNTHROID-1 MG. 
DEXAMETHASONE TAXOL 
DEXAMETHASONE/DECADRON TEQUIN/GATIFLOXACIN 
DEXAMETHAZONE TERBINAFINE HCL 
DILANTIN TERBINAFINE/LAMISIL 
DILANTIN/PHENYTOIN TEROZASIN 
DIURETIC LASIX TESTOSTERONE (ANDRODERM PATCH) 
DOXERCALCIFEROL (FOR 
PARATHYROID) 
TESVOSVERONE 
DOXYCYCLINE TETRACYCLINE 
DOXYCYLINE THALIDOMIDE 
ECOTRIN THERAFLU 
EFUDEX TOLTERODINE TARTRATE/DETROL 
ENDOCET TOOK 1ST NAPROSYN-" 
ENDOCET/PERCOCET TOOK 2ND RELAFEN-" 
ENDOCOT (STOOL SOFTENER) TOPAMAX (MIGRANES) 
ENSURE TRAMADOL 
ERYTHROMYCIN TRAMADOL/CENTRAL ANALGESIC 
ERYTHROPOIETIN TRAZAD 
ERYTHROPOIETIN/EPOGEN TRAZADONE 
ERYTHROPOIETIN-EPOGEN TRAZADONE HCL 
ESTRACE TRAZODONE 
ETODOLAC/FOR PAIN TRENTAL 400MG PO TID 
ETOPOSIDE TRIAMCINOLONE 
EXCEDRIN TENSION HEADACHE TRIAMCINOLONE CREAM 
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EXTRA STRENGTH TYLENOL TRIAMCINOTONE CREAM 
FLAGYL TRICOR 
FLAGYL/METRONIDAZOLE TRICOR/FENOFIBBRATE 
FLORAZEMIDE TYLENOL 
FLUDROCORTISONE ACETATE TYLENOL 3 
FLUOXETINE TYLENOL 500 
FLUROSEMIDE TYLENOL COLD 
FLUROSIMIDE TYLENOL COLD & SINUS 
FRESH FROZEN PLASMA TYLENOL PM 
FUOROSEMIDE TYLENOL PM (PRN) 
FUROSEMIDE TYLENOL PRN. 
FUROSEMIDE / DUIRETIC TYLENOL SINUS 
FUROSEMIDE 40MG DAILY TYLENOL W/CODEINE 
FUROSEMIDE/DIURETIC TYLENOL WITH CODEINE 
FUROSEMIDE/DUIRECTIC TYLENOL/CODENE 
FUROSEMIDE/DUIRETIC TYLOX 
FUROSEMIDE/H20 PILL ULTRACET 
FUROSEMIDE/LASIX ULTRACET MCN 2 EVERY 4-6 HR. AS 
NEEDED 
FUROSEMIDE-DUIRETIC ULTRAM 
FUROSIMIDE/H2O PILL VALPROIC ACID 
GATIFLOXACIN VICODAN 
GEMFIBROZIL VIOX 
GENERIC PERCOCET VIOXX 
GLUCOSAMINE/CHONDROITIN VIRACEPT 
H2O PILL - LASIX (GENERIC) VIT C 
H2O PILL-HYDROCHLOROTHIAZIDE VIT E 
H2O PILLS/FUROSEMIDE VITAMIN C 
HALOPERIDOL VITAMIN E 
HCLT VITAMIN K. 
HCT2 VYTORIN 
HCTZ XELODA 
HCTZ (DIURETIC) XELODA (XELODA) 
HCTZ (HYDROCHLOROTHIAZIDE) ZANTAC 
HCTZ/HYDROCHLOROTHIAZIDE ZAROXALYN (METOLAZONE) 
HCTZ/TRIAMTERENE ZITHRO PAC 
HTCL ZITHROMAX 
HTCZ ZITHROMYCIN 
HYDR0CHLOROTHIAZIDE ZOLOFT 
HYDROCHLOROTHIAZIDE ZOLOFT/SERTRALINE 
HYDROCHLOROTHIAZIDE (HCTZ) ZOSYN 
HYDROCHLORTHESIDE/HCTZ ZOSYN ONE DOSE 
HYDROCHLORTHIA ZIOLE Z-PAC 
HYDROCHLORTHIAZIDE Z-PAC/ZITHROMAX 
HYDROCHLORTHIZIDE Z-PACK 
HYDROCHLOTHIAZID Z-PACK ANTIBIOTIC (TOOK 9-23 TO 9-28) 
HYDROCO/APAP Z-PACK-5 DA ONLY 
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HYDROCORTISONE Z-PAK/ZITHROMAX 
HYZAAR ZYRTEC/CETIRIZINE 
IBUPROFEN  
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